SG11201500239VA - Asymmetric auxiliary group - Google Patents

Asymmetric auxiliary group

Info

Publication number: SG11201500239VA
Authority: SG; Singapore
Prior art keywords: auxiliary group; asymmetric auxiliary; asymmetric; group; auxiliary
Prior art date: 2012-07-13

Application number

SG11201500239VA

Inventor

Mamoru Shimizu

Takeshi Wada

Original Assignee

Wave Life Sciences Japan

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-07-13

Filing date

2013-07-12

Publication date

2015-03-30

2013-07-12 Application filed by Wave Life Sciences Japan filed Critical Wave Life Sciences Japan

2015-03-30 Publication of SG11201500239VA publication Critical patent/SG11201500239VA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
- C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
- C07F9/65844—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a five-membered ring which may be condensed with another ring system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B53/00—Asymmetric syntheses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/11—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Engineering & Computer Science (AREA)
Saccharide Compounds (AREA)
Pyrrole Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Plural Heterocyclic Compounds (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

SG11201500239VA 2012-07-13 2013-07-12 Asymmetric auxiliary group SG11201500239VA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261671652P	2012-07-13	2012-07-13
PCT/JP2013/004303 WO2014010250A1 (en)	2012-07-13	2013-07-12	Asymmetric auxiliary group

Publications (1)

Publication Number	Publication Date
SG11201500239VA true SG11201500239VA (en)	2015-03-30

Family

ID=49915731

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201500239VA SG11201500239VA (en)	2012-07-13	2013-07-12	Asymmetric auxiliary group

Country Status (15)

Country	Link
US (5)	US9598458B2 (en)
EP (2)	EP3812370A1 (en)
JP (5)	JP6268157B2 (en)
KR (1)	KR101850319B1 (en)
CN (2)	CN104684893B (en)
AU (5)	AU2013288048A1 (en)
BR (1)	BR112015000784A8 (en)
CA (1)	CA2879023C (en)
DK (1)	DK2872485T3 (en)
ES (1)	ES2862073T3 (en)
PL (1)	PL2872485T3 (en)
PT (1)	PT2872485T (en)
RU (1)	RU2693381C2 (en)
SG (1)	SG11201500239VA (en)
WO (1)	WO2014010250A1 (en)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2370451B1 (en)	2008-12-02	2016-11-16	Wave Life Sciences Japan, Inc.	Method for the synthesis of phosphorus atom modified nucleic acids
KR101885383B1 (en)	2009-07-06	2018-08-03	웨이브 라이프 사이언시스 리미티드	Novel nucleic acid prodrugs and methods of use thereof
US10428019B2 (en) *	2010-09-24	2019-10-01	Wave Life Sciences Ltd.	Chiral auxiliaries
AU2012284265B2 (en)	2011-07-19	2017-08-17	Wave Life Sciences Ltd.	Methods for the synthesis of functionalized nucleic acids
SG11201500239VA (en) *	2012-07-13	2015-03-30	Wave Life Sciences Japan	Asymmetric auxiliary group
BR112015000723A2 (en)	2012-07-13	2017-06-27	Shin Nippon Biomedical Laboratories Ltd	chiral nucleic acid adjuvant
SG11201500232UA (en)	2012-07-13	2015-04-29	Wave Life Sciences Pte Ltd	Chiral control
WO2015108047A1 (en)	2014-01-15	2015-07-23	株式会社新日本科学	Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
JPWO2015108046A1 (en)	2014-01-15	2017-03-23	株式会社新日本科学	Chiral nucleic acid adjuvant and antiallergic agent having antiallergic action
US10149905B2 (en)	2014-01-15	2018-12-11	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
SG10201912897UA (en)	2014-01-16	2020-02-27	Wave Life Sciences Ltd	Chiral design
RU2708237C2 (en)	2014-08-22	2019-12-05	Общество с ограниченной ответственностью "НооГен"	Modified oligonucleotides and method for production thereof
JP6689279B2 (en)	2014-12-16	2020-05-20	ロシュイノベーションセンターコペンハーゲンエーエス	Chiral toxicity screening method
DK3234134T3 (en)	2014-12-17	2020-07-27	Proqr Therapeutics Ii Bv	TARGETED RNA EDITING
MA43072A (en)	2015-07-22	2018-05-30	Wave Life Sciences Ltd	COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
WO2017062862A2 (en)	2015-10-09	2017-04-13	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods thereof
CN108779132B (en)	2016-03-13	2022-04-15	波涛生命科学有限公司	Compositions and methods for phosphoramidite and oligonucleotide synthesis
AU2017235278C1 (en)	2016-03-14	2022-03-10	F. Hoffmann-La Roche Ag	Oligonucleotides for reduction of PD-L1 expression
US11267843B2 (en) *	2016-03-18	2022-03-08	Roche Innovation Center Copenhagen A/S	Stereodefining L-monomers
CN109414511B (en)	2016-04-18	2023-05-23	萨勒普塔医疗公司	Antisense oligomers for treating diseases associated with acid alpha-glucosidase genes and methods of use thereof
BR112018072279A2 (en)	2016-04-29	2019-02-12	Sarepta Therapeutics, Inc.	oligonucleotide analogues targeting human lmna
MA45270A (en)	2016-05-04	2017-11-09	Wave Life Sciences Ltd	COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
US11261209B2 (en)	2016-05-12	2022-03-01	Roche Innovation Center Copenhagen A/S	Enhanced coupling of stereodefined oxazaphospholidine phosphoramidite monomers to nucleoside or oligonucleotide
US10882884B2 (en)	2016-05-18	2021-01-05	Eth Zurich	Stereoselective synthesis of phosphorothioate oligoribonucleotides
US11013757B2 (en)	2016-06-03	2021-05-25	Wave Life Sciences Ltd.	Oligonucleotides, compositions and methods thereof
KR102418185B1 (en)	2016-06-22	2022-07-06	프로큐알 테라퓨틱스 Ⅱ 비.브이.	Single-stranded RNA-editing oligonucleotides
MX2018016052A (en)	2016-06-30	2019-05-02	Sarepta Therapeutics Inc	Exon skipping oligomers for muscular dystrophy.
KR20190027373A (en)	2016-07-05	2019-03-14	바이오마린 테크놀로지스 비.브이.	Pre-MRNA splice switching or modified oligonucleotides, including improved non-cyclic scaffold moieties, for genetic disorder treatment
AU2017312116A1 (en)	2016-08-17	2019-03-07	Solstice Biologics, Ltd.	Polynucleotide constructs
CN110352244B (en)	2016-09-01	2023-03-21	ProQR治疗上市公司Ⅱ	Chemically modified RNA editing single stranded oligonucleotides
WO2018098264A1 (en) *	2016-11-23	2018-05-31	Wave Life Sciences Ltd.	Compositions and methods for phosphoramidite and oligonucleotide synthesis
KR20230110811A (en)	2016-12-19	2023-07-25	사렙타 쎄러퓨틱스 인코퍼레이티드	Exon skipping oligomer conjugates for muscular dystrophy
PT3554554T (en)	2016-12-19	2022-11-08	Sarepta Therapeutics Inc	Exon skipping oligomer conjugates for muscular dystrophy
PT3554552T (en)	2016-12-19	2022-10-03	Sarepta Therapeutics Inc	Exon skipping oligomer conjugates for muscular dystrophy
KR20180076661A (en) *	2016-12-28	2018-07-06	엘지디스플레이 주식회사	Substrate for display and display including the same
CA3058966A1 (en)	2017-04-14	2018-10-18	Tollnine, Inc.	Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
US11603532B2 (en)	2017-06-02	2023-03-14	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods of use thereof
EP3630789A4 (en)	2017-06-02	2021-06-16	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods of use thereof
WO2018237194A1 (en) *	2017-06-21	2018-12-27	Wave Life Sciences Ltd.	Compounds, compositions and methods for synthesis
EP3645544B1 (en)	2017-06-28	2023-05-10	Roche Innovation Center Copenhagen A/S	Multiple coupling&oxidation method
US11597744B2 (en)	2017-06-30	2023-03-07	Sirius Therapeutics, Inc.	Chiral phosphoramidite auxiliaries and methods of their use
AU2018316159A1 (en)	2017-08-08	2020-02-06	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods thereof
JP7472018B2 (en) *	2017-09-18	2024-04-22	ウェーブライフサイエンシーズリミテッド	Techniques for preparing oligonucleotides
EA201991450A1 (en)	2017-09-22	2019-12-30	Сарепта Терапьютикс, Инк.	OLIGOMER CONJUGATES FOR EXONISM SKIP IN MUSCULAR DYSTROPHY
WO2019067975A1 (en)	2017-09-28	2019-04-04	Sarepta Therapeutics, Inc.	Combination therapies for treating muscular dystrophy
US20200254002A1 (en)	2017-09-28	2020-08-13	Sarepta Therapeutics, Inc.	Combination therapies for treating muscular dystrophy
WO2019067981A1 (en)	2017-09-28	2019-04-04	Sarepta Therapeutics, Inc.	Combination therapies for treating muscular dystrophy
JP2020537518A (en)	2017-10-12	2020-12-24	ウェーブライフサイエンシーズリミテッド	Oligonucleotide composition and its method
EP3697910A4 (en)	2017-10-18	2021-07-14	Sarepta Therapeutics, Inc.	Antisense oligomer compounds
JPWO2019187691A1 (en)	2018-03-26	2021-03-25	株式会社カネカ	Polypeptide having collagenase activity and its production method
US10765760B2 (en)	2018-05-29	2020-09-08	Sarepta Therapeutics, Inc.	Exon skipping oligomer conjugates for muscular dystrophy
EP4219717A3 (en)	2018-06-13	2023-12-20	Sarepta Therapeutics, Inc.	Exon skipping oligomers for muscular dystrophy
TW202020153A (en)	2018-07-27	2020-06-01	美商薩羅塔治療公司	Exon skipping oligomers for muscular dystrophy
AU2019370937A1 (en)	2018-11-02	2021-05-27	Biomarin Technologies B.V.	Bispecific antisense oligonucleotides for dystrophin exon skipping
BR112021011018A2 (en)	2018-12-13	2021-08-31	Sarepta Therapeutics, Inc.	EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY
KR20210149750A (en) *	2019-03-20	2021-12-09	웨이브 라이프 사이언시스 리미티드	Techniques useful for preparing oligonucleotides
JPWO2020196890A1 (en)	2019-03-28	2020-10-01
US20220194976A1 (en) *	2019-04-16	2022-06-23	Roche Innovation Center Copenhagen A/S	Novel Process for Preparing Nucleotide P(V) Monomers
WO2020214763A1 (en)	2019-04-18	2020-10-22	Sarepta Therapeutics, Inc.	Compositions for treating muscular dystrophy
CA3179051A1 (en)	2020-05-22	2021-11-25	Chandra Vargeese	Double stranded oligonucleotide compositions and methods relating thereto
CA3226001A1 (en)	2021-07-16	2023-01-19	Anton Jan Van Zonneveld	Oligonucleotide for inhibiting quaking activity
AU2022358322A1 (en)	2021-09-30	2024-05-16	Sarepta Therapeutics, Inc.	Antisense oligonucleotides having one or more abasic units
CN118660876A (en) *	2022-02-11	2024-09-17	波涛生命科学有限公司	Stereoselective techniques for chiral compounds
WO2023152371A1 (en)	2022-02-14	2023-08-17	Proqr Therapeutics Ii B.V.	Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
TW202400187A (en)	2022-05-06	2024-01-01	萊登大學醫院萊登大學醫學中心	Oligonucleotide
WO2024013360A1 (en)	2022-07-15	2024-01-18	Proqr Therapeutics Ii B.V.	Chemically modified oligonucleotides for adar-mediated rna editing
WO2024013361A1 (en)	2022-07-15	2024-01-18	Proqr Therapeutics Ii B.V.	Oligonucleotides for adar-mediated rna editing and use thereof
WO2024022911A1 (en)	2022-07-25	2024-02-01	Vico Therapeutics B.V.	Antisense oligonucleotides for treating a disease or condition associated with an abnormal processing of app
WO2024064237A2 (en)	2022-09-21	2024-03-28	Sarepta Therapeutics, Inc.	Dmd antisense oligonucleotide-mediated exon skipping efficiency
GB202215614D0 (en)	2022-10-21	2022-12-07	Proqr Therapeutics Ii Bv	Heteroduplex rna editing oligonucleotide complexes
WO2024110565A1 (en)	2022-11-24	2024-05-30	Proqr Therapeutics Ii B.V.	Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis
GB202218090D0 (en)	2022-12-01	2023-01-18	Proqr Therapeutics Ii Bv	Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
WO2024121373A1 (en)	2022-12-09	2024-06-13	Proqr Therapeutics Ii B.V.	Antisense oligonucleotides for the treatment of cardiovascular disease
GB202300865D0 (en)	2023-01-20	2023-03-08	Proqr Therapeutics Ii Bv	Delivery of oligonucleotides
WO2024175550A1 (en)	2023-02-20	2024-08-29	Proqr Therapeutics Ii B.V.	Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease
GB202304363D0 (en)	2023-03-24	2023-05-10	Proqr Therapeutics Ii Bv	Chemically modified antisense oligonucleotides for use in RNA editing
WO2024206175A1 (en)	2023-03-24	2024-10-03	Proqr Therapeutics Ii B.V.	Antisense oligonucleotides for the treatment of neurological disorders
WO2024200472A1 (en)	2023-03-27	2024-10-03	Proqr Therapeutics Ii B.V.	Antisense oligonucleotides for the treatment of liver disease
WO2024227040A1 (en)	2023-04-27	2024-10-31	Sarepta Therapeutics, Inc.	Antisense oligomers for treatment of chronic kidney disease

Family Cites Families (703)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2878264A (en)		1959-03-17		Substituted amino alcohols
CH372667A (en)	1957-09-26	1963-10-31	Robins Co Inc A H	Process for the preparation of 3-aryl-3-pyrrolidinols
US3135766A (en)	1961-10-03	1964-06-02	Mead Johnson & Co	3-substituted-3-pyrrolidinols
US3484473A (en)	1967-05-12	1969-12-16	Buckman Labor Inc	Methylene bisesters of thiolsulfonic acids
DE1934150A1 (en)	1968-07-10	1970-01-15	Pennwalt Corp	New 1-alkanoyloxy-1,2,4,5-tetrahydro-3H, 3-benzazepine
US3687808A (en)	1969-08-14	1972-08-29	Univ Leland Stanford Junior	Synthetic polynucleotides
US3745162A (en)	1970-08-31	1973-07-10	Robins Co Inc A H	1,2,3,4-tetrahydroisoquinoline-2-(thio)-carboxamides
GB1448437A (en)	1973-02-24	1976-09-08	Beecham Group Ltd	Diphenylpropylamines
US4022791A (en)	1975-06-03	1977-05-10	Pfizer Inc.	2-Aminomethyl-3,4-dihydronaphthalenes
GB1504424A (en)	1975-08-09	1978-03-22	Beecham Group Ltd	Isoquinoline-derived aminoethers
BR7807288A (en)	1977-11-08	1979-06-12	Genentech Inc	POLYNUCLEOTIDE SYNTHESIS PROCESS
DD133885B1 (en)	1978-01-04	1981-02-25	Hans Lehmann	AGENTS FOR THE CONTROL OF PHYTOPATHOGENIC BACTERIA AND MUSHROOMS
US4500707A (en)	1980-02-29	1985-02-19	University Patents, Inc.	Nucleosides useful in the preparation of polynucleotides
US5132418A (en)	1980-02-29	1992-07-21	University Patents, Inc.	Process for preparing polynucleotides
US4458066A (en)	1980-02-29	1984-07-03	University Patents, Inc.	Process for preparing polynucleotides
US4415732A (en)	1981-03-27	1983-11-15	University Patents, Inc.	Phosphoramidite compounds and processes
US4668777A (en)	1981-03-27	1987-05-26	University Patents, Inc.	Phosphoramidite nucleoside compounds
US4973679A (en)	1981-03-27	1990-11-27	University Patents, Inc.	Process for oligonucleo tide synthesis using phosphormidite intermediates
US4542142A (en)	1982-11-22	1985-09-17	Roussel Uclaf	Insecticidal cyclopropane carboxylic acid derivatives with 3-unsaturated-side chain
DE3329892A1 (en)	1983-08-18	1985-03-07	Köster, Hubert, Prof. Dr., 2000 Hamburg	METHOD FOR PRODUCING OLIGONUCLEOTIDES
US5118800A (en)	1983-12-20	1992-06-02	California Institute Of Technology	Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5643889A (en)	1984-07-11	1997-07-01	Temple University-Of The Commonwealth System Of Pennsylvania	Cholesterol conjugates of 2'5'-oligoadenylate derivatives and antiviral uses thereof
FR2567892B1 (en)	1984-07-19	1989-02-17	Centre Nat Rech Scient	NOVEL OLIGONUCLEOTIDES, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS AS MEDIATORS IN DEVELOPING THE EFFECTS OF INTERFERONS
US5367066A (en)	1984-10-16	1994-11-22	Chiron Corporation	Oligonucleotides with selectably cleavable and/or abasic sites
FR2575751B1 (en)	1985-01-08	1987-04-03	Pasteur Institut	NOVEL ADENOSINE DERIVATIVE NUCLEOSIDES, THEIR PREPARATION AND THEIR BIOLOGICAL APPLICATIONS
FR2576898B1 (en)	1985-02-01	1988-01-08	Lafon Labor	3-PHENYL-TETRAHYDROPYRIDINE DERIVATIVES, METHOD OF PREPARATION AND THERAPEUTIC USE
US4659774A (en)	1985-11-01	1987-04-21	American Hoechst Corporation	Support for solid-phase oligonucleotide synthesis
US4666777A (en)	1985-12-23	1987-05-19	The Dow Chemical Company	Structured latex core-shell polymer particles suitable for use in the preparation of composite sheets
US4735949A (en)	1986-02-18	1988-04-05	Warner-Lambert Company	Disubstituted-7-pyrrolidinonaphthyridine antibacterial agents
US4840956A (en)	1986-02-18	1989-06-20	Warner-Lambert Company	Novel disubstituted-7-pyrrolidinoquinoline antibacterial agents
IL83663A0 (en)	1986-10-27	1988-01-31	Robins Co Inc A H	Preparation of 3-pyrrolidinols
WO1988010264A1 (en)	1987-06-24	1988-12-29	Howard Florey Institute Of Experimental Physiology	Nucleoside derivatives
EP0302349B1 (en)	1987-07-30	1993-09-29	Bar Ilan University	Biologically active carboxylic acid esters
US4923901A (en)	1987-09-04	1990-05-08	Millipore Corporation	Membranes with bound oligonucleotides and peptides
US5175273A (en)	1988-07-01	1992-12-29	Genentech, Inc.	Nucleic acid intercalating agents
US4945158A (en)	1988-08-12	1990-07-31	American Cyanamid Company	Antidiabetic phosphonates
US4943629A (en)	1988-08-12	1990-07-24	American Cyanamid Company	Antidiabetic alpha-substituted phosphonates
US5262530A (en)	1988-12-21	1993-11-16	Applied Biosystems, Inc.	Automated system for polynucleotide synthesis and purification
US5047524A (en)	1988-12-21	1991-09-10	Applied Biosystems, Inc.	Automated system for polynucleotide synthesis and purification
US5141813A (en)	1989-08-28	1992-08-25	Clontech Laboratories, Inc.	Multifunctional controlled pore glass reagent for solid phase oligonucleotide synthesis
US5134066A (en)	1989-08-29	1992-07-28	Monsanto Company	Improved probes using nucleosides containing 3-dezauracil analogs
CA2029273A1 (en)	1989-12-04	1991-06-05	Christine L. Brakel	Modified nucleotide compounds
JPH05503517A (en)	1989-12-18	1993-06-10	バージニア・コモンウェルス・ユニバーシティ	Sigma receptor ligand and its uses
US5130302A (en)	1989-12-20	1992-07-14	Boron Bilogicals, Inc.	Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5587470A (en)	1990-01-11	1996-12-24	Isis Pharmaceuticals, Inc.	3-deazapurines
BR9105935A (en)	1990-01-11	1992-11-17	Isis Pharmaceuticals Inc	COMPOSITION, OLIGONUCLEOTIDEO ANALOG, MIXED SEQUENCED OLIGONUCLEOTIDEO, PROCESS FOR THE PREPARATION OF 2'-SUBSTITUTED NUCLEOSASES PREPARATION, COMPOSITION TO MODULATE THE RNA ACTIVITY, PROCESSES TO MODULAR THE PRODUCTION OF A PROTEIN FOR AN ORGANIC PROTECTION OR ABSENCE OF RNA, OLIGONUCLEOTIDEO OR NUCLEASE RESISTANT OLIGONUCLEOTIDE ANALOG ANALOG AND PROCESS TO TREAT AN ORGANISM HAVING A DISEASE
US5459255A (en)	1990-01-11	1995-10-17	Isis Pharmaceuticals, Inc.	N-2 substituted purines
US5914396A (en)	1990-01-11	1999-06-22	Isis Pharmaceuticals, Inc.	2'-O-modified nucleosides and phosphoramidites
US5620963A (en)	1991-10-15	1997-04-15	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity
US5457191A (en)	1990-01-11	1995-10-10	Isis Pharmaceuticals, Inc.	3-deazapurines
US5587361A (en)	1991-10-15	1996-12-24	Isis Pharmaceuticals, Inc.	Oligonucleotides having phosphorothioate linkages of high chiral purity
US5681941A (en)	1990-01-11	1997-10-28	Isis Pharmaceuticals, Inc.	Substituted purines and oligonucleotide cross-linking
US7101993B1 (en)	1990-01-11	2006-09-05	Isis Pharmaceuticals, Inc.	Oligonucleotides containing 2′-O-modified purines
US5646265A (en)	1990-01-11	1997-07-08	Isis Pharmceuticals, Inc.	Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5506212A (en)	1990-01-11	1996-04-09	Isis Pharmaceuticals, Inc.	Oligonucleotides with substantially chirally pure phosphorothioate linkages
US5635488A (en)	1991-10-15	1997-06-03	Isis Pharmaceuticals, Inc.	Compounds having phosphorodithioate linkages of high chiral purity
US5212295A (en)	1990-01-11	1993-05-18	Isis Pharmaceuticals	Monomers for preparation of oligonucleotides having chiral phosphorus linkages
US5852188A (en)	1990-01-11	1998-12-22	Isis Pharmaceuticals, Inc.	Oligonucleotides having chiral phosphorus linkages
US6339066B1 (en)	1990-01-11	2002-01-15	Isis Pharmaceuticals, Inc.	Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
US5292875A (en)	1990-04-20	1994-03-08	Lynx Therapeutics, Inc.	Method of synthesizing sulfurized oligonucleotide analogs
US5151510A (en)	1990-04-20	1992-09-29	Applied Biosystems, Inc.	Method of synethesizing sulfurized oligonucleotide analogs
AU649458B2 (en)	1990-05-23	1994-05-26	Isis Pharmaceuticals, Inc.	Compositions and methods for modulating RNA activity through modification of the 5' cap structure of RNA
US5610289A (en)	1990-07-27	1997-03-11	Isis Pharmaceuticals, Inc.	Backbone modified oligonucleotide analogues
US5783682A (en)	1990-07-27	1998-07-21	Isis Pharmaceuticals, Inc.	Oligonucleotide mimics having nitrogen-containing linkages
US5378825A (en)	1990-07-27	1995-01-03	Isis Pharmaceuticals, Inc.	Backbone modified oligonucleotide analogs
US5602240A (en)	1990-07-27	1997-02-11	Ciba Geigy Ag.	Backbone modified oligonucleotide analogs
US6087482A (en)	1990-07-27	2000-07-11	Isis Pharmaceuticals, Inc.	Heteroatomic oligonucleoside linkages
US5138045A (en)	1990-07-27	1992-08-11	Isis Pharmaceuticals	Polyamine conjugated oligonucleotides
US5386023A (en)	1990-07-27	1995-01-31	Isis Pharmaceuticals	Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5223618A (en)	1990-08-13	1993-06-29	Isis Pharmaceuticals, Inc.	4'-desmethyl nucleoside analog compounds
US5489677A (en)	1990-07-27	1996-02-06	Isis Pharmaceuticals, Inc.	Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5688941A (en)	1990-07-27	1997-11-18	Isis Pharmaceuticals, Inc.	Methods of making conjugated 4' desmethyl nucleoside analog compounds
US5623070A (en)	1990-07-27	1997-04-22	Isis Pharmaceuticals, Inc.	Heteroatomic oligonucleoside linkages
WO1992002258A1 (en)	1990-07-27	1992-02-20	Isis Pharmaceuticals, Inc.	Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
US5541307A (en)	1990-07-27	1996-07-30	Isis Pharmaceuticals, Inc.	Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5792844A (en)	1990-07-27	1998-08-11	Isis Pharmaceuticals, Inc.	Oligonucleoside linkages containing adjacent nitrogen atoms
US5998603A (en)	1994-09-29	1999-12-07	Isis Pharmaceuticals, Inc.	4'-desmethyl nucleoside analogs, and oligomers thereof
US5608046A (en)	1990-07-27	1997-03-04	Isis Pharmaceuticals, Inc.	Conjugated 4'-desmethyl nucleoside analog compounds
US6121433A (en)	1990-07-27	2000-09-19	Isis Pharmaceuticals, Inc.	Oligomeric compounds having nitrogen-containing linkages
WO1994022886A1 (en)	1993-03-30	1994-10-13	Isis Pharmaceuticals, Inc.	Heteroatomic oligonucleoside linkages
US5618704A (en)	1990-07-27	1997-04-08	Isis Pharmacueticals, Inc.	Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5834607A (en)	1990-07-27	1998-11-10	Isis Pharmaceuticals, Inc.	Amines and methods of making and using the same
US5677437A (en)	1990-07-27	1997-10-14	Isis Pharmaceuticals, Inc.	Heteroatomic oligonucleoside linkages
US5432272A (en)	1990-10-09	1995-07-11	Benner; Steven A.	Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5512668A (en)	1991-03-06	1996-04-30	Polish Academy Of Sciences	Solid phase oligonucleotide synthesis using phospholane intermediates
US7015315B1 (en)	1991-12-24	2006-03-21	Isis Pharmaceuticals, Inc.	Gapped oligonucleotides
US20020183502A1 (en)	1991-05-21	2002-12-05	Mesmaeker Alain De	Backbone-modified oligonucleotide analogs and methods for using same
JPH04348077A (en)	1991-05-24	1992-12-03	Nec Corp	Thin-film transistor
US6414112B1 (en)	1991-05-24	2002-07-02	Ole Buchardt	Peptide nucleic acids having 2,6-diaminopurine nucleobases
CA2111108A1 (en)	1991-06-10	1992-12-23	Joong Myung Cho	Hepatitis c diagnostics and vaccines
US5359052A (en)	1991-08-05	1994-10-25	Polish Academy Of Sciences	Chalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates
US5646267A (en)	1991-08-05	1997-07-08	Polish Academy Of Sciences	Method of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues
US6369209B1 (en)	1999-05-03	2002-04-09	Isis Pharmaceuticals, Inc.	Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US7119184B2 (en)	1991-08-12	2006-10-10	Isis Pharmaceuticals, Inc.	Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US5599797A (en)	1991-10-15	1997-02-04	Isis Pharmaceuticals, Inc.	Oligonucleotides having phosphorothioate linkages of high chiral purity
US5576302A (en)	1991-10-15	1996-11-19	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
US5607923A (en)	1991-10-15	1997-03-04	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity
DE69232699T2 (en)	1991-10-15	2003-02-06	Isis Pharmaceutical, Inc.	OLIGONUCLEOTIDES BONDED BY CHIRAL PHOSPHORATOMES
US5661134A (en)	1991-10-15	1997-08-26	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
US5654284A (en)	1991-10-15	1997-08-05	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating RAF kinase having phosphorothioate linkages of high chiral purity
DE59208572D1 (en)	1991-10-17	1997-07-10	Ciba Geigy Ag	Bicyclic nucleosides, oligonucleotides, processes for their preparation and intermediates
US5594121A (en)	1991-11-07	1997-01-14	Gilead Sciences, Inc.	Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US6235887B1 (en)	1991-11-26	2001-05-22	Isis Pharmaceuticals, Inc.	Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
US5484908A (en)	1991-11-26	1996-01-16	Gilead Sciences, Inc.	Oligonucleotides containing 5-propynyl pyrimidines
US5359044A (en)	1991-12-13	1994-10-25	Isis Pharmaceuticals	Cyclobutyl oligonucleotide surrogates
AU669353B2 (en)	1991-12-24	1996-06-06	Isis Pharmaceuticals, Inc.	Gapped 2' modified oligonucleotides
GB9213601D0 (en)	1992-06-26	1992-08-12	Mastico Robert A	Protein based delivery system
US7067497B2 (en)	1992-09-29	2006-06-27	Isis Pharmaceuticals, Inc.	Modulation of telomere length by oligonucleotides having a G-core sequence
US6444656B1 (en)	1992-12-23	2002-09-03	Biochem Pharma, Inc.	Antiviral phosphonate nucleotides
US6005107A (en)	1992-12-23	1999-12-21	Biochem Pharma, Inc.	Antiviral compounds
DK0677056T3 (en)	1993-01-25	1996-08-05	Hybridon Inc	Oligonucleotide alkyl phosphonates and alkyl phosphonothioates
JPH08508490A (en)	1993-03-31	1996-09-10	スターリングウィンスロップインコーポレイティド	Novel 5'-substituted nucleosides and oligomers obtained therefrom
JPH08508489A (en)	1993-03-31	1996-09-10	スターリングウィンスロップインコーポレイティド	Bifunctional nucleosides, oligomers thereof and methods for their production and use
US5955591A (en)	1993-05-12	1999-09-21	Imbach; Jean-Louis	Phosphotriester oligonucleotides, amidites and method of preparation
US6015886A (en)	1993-05-24	2000-01-18	Chemgenes Corporation	Oligonucleotide phosphate esters
DE69412704T2 (en)	1993-06-10	1999-02-04	Idemitsu Petrochemical Co., Ltd., Tokio/Tokyo	Injection mold
US5502177A (en)	1993-09-17	1996-03-26	Gilead Sciences, Inc.	Pyrimidine derivatives for labeled binding partners
US5643989A (en)	1993-10-29	1997-07-01	Azdel, Inc.	Fiber reinforced functionalized polyolefin composites
US5457187A (en)	1993-12-08	1995-10-10	Board Of Regents University Of Nebraska	Oligonucleotides containing 5-fluorouracil
DE4435728A1 (en)	1994-01-19	1995-07-20	Boehringer Mannheim Gmbh	Biotin silane compounds and binding matrix containing these compounds
US6117679A (en)	1994-02-17	2000-09-12	Maxygen, Inc.	Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
CN1077598C (en)	1994-02-22	2002-01-09	诺沃奇梅兹有限公司	A method of preparing a variant of a lipolytic enzyme
US5596091A (en)	1994-03-18	1997-01-21	The Regents Of The University Of California	Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
EP0759073A1 (en)	1994-05-11	1997-02-26	Novo Nordisk A/S	AN ENZYME WITH ENDO-1,3(4)-$g(b)-GLUCANASE ACTIVITY
US5525711A (en)	1994-05-18	1996-06-11	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Pteridine nucleotide analogs as fluorescent DNA probes
HRP950288A2 (en)	1994-05-31	1997-08-31	Bayer Ag	Oxalylamino-benzofuran- and benzothienyl-derivatives
EP0685475B1 (en)	1994-05-31	1999-01-13	Bayer Ag	Amino-benzofuryl-and thienyl-derivatives
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
EP1167378B1 (en)	1994-07-15	2011-05-11	University of Iowa Research Foundation	Immunomodulatory oligonucleotides
US6239116B1 (en)	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
WO1996007392A2 (en)	1994-09-07	1996-03-14	Hybridon, Inc.	Oligonucleotide prodrugs
US5681940A (en)	1994-11-02	1997-10-28	Icn Pharmaceuticals	Sugar modified nucleosides and oligonucleotides
AU4514696A (en)	1994-12-22	1996-07-10	Hybridon, Inc.	Synthesis of stereospecific oligonucleotide phosphorothioates
GB9501465D0 (en)	1995-01-25	1995-03-15	King S College London	Nucleoside phosphorothioate derivatives,synthesis and use thereof
US6166197A (en)	1995-03-06	2000-12-26	Isis Pharmaceuticals, Inc.	Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
WO1996027606A1 (en)	1995-03-06	1996-09-12	Isis Pharmaceuticals, Inc.	Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
DE69638104D1 (en)	1995-04-27	2010-02-11	Takara Bio Inc	Gene coding for lacto-N-biosidase
US6004813A (en)	1995-05-11	1999-12-21	Applied Research Systems Ars Holding N.V.	Il-6 activity inhibitor
JPH11507020A (en)	1995-05-19	1999-06-22	グリコメド・インコーポレイテッド	Collection of activated glycoside compounds and their biological use
ATE194990T1 (en)	1995-05-23	2000-08-15	Hybridon Inc	SYNTHON FOR STEREOSELECTIVE OLIGONUCLEOTIDE SYNTHESIS
AU5871196A (en)	1995-05-23	1996-12-24	Hybridon, Inc.	Methods and compounds for the synthesis of oligonucleotides and the oligonucleotides thereby produced
JPH10510433A (en)	1995-06-06	1998-10-13	アイシス・ファーマシューティカルス・インコーポレーテッド	Oligonucleotides with high chiral purity phosphorothioate linkages
US5932450A (en)	1995-06-07	1999-08-03	Gen-Probe Incorporated	Enzymatic synthesis of oligonucleotides using digestible templates
US5824503A (en)	1995-06-29	1998-10-20	Takara Shuzo Co, Ltd.	Gene encoding endoglycoceramidase activator
EP0751222B1 (en)	1995-06-29	2006-03-01	Takara Bio Inc.	Gene encoding endoglycoceramidase
US6017700A (en)	1995-08-04	2000-01-25	Bayer Corporation	Cationic oligonucleotides, and related methods of synthesis and use
US5936080A (en)	1996-05-24	1999-08-10	Genta Incorporated	Compositions and methods for the synthesis of organophosphorus derivatives
WO1997009443A1 (en)	1995-09-05	1997-03-13	Michigan State University	PROCESS FOR THE ISOLATION AND PURIFICATION OF TAXOL AND TAXANES FROM TAXUS spp
US5734041A (en)	1995-10-20	1998-03-31	Mcgill University	Preparation of chiral phosphorothioate oligomers
US6160109A (en)	1995-10-20	2000-12-12	Isis Pharmaceuticals, Inc.	Preparation of phosphorothioate and boranophosphate oligomers
US6476216B1 (en)	1995-10-20	2002-11-05	Mcgill University	Preparation of phosphorothioate oligomers
US7018793B1 (en)	1995-12-07	2006-03-28	Diversa Corporation	Combinatorial screening of mixed populations of organisms
CN1215994A (en)	1996-02-15	1999-05-05	国家健康学会	Rnase L activators and antisense oligonucleotides effective to treat RSV infections
US6214805B1 (en)	1996-02-15	2001-04-10	The United States Of America As Represented By The Department Of Health And Human Services	RNase L activators and antisense oligonucleotides effective to treat RSV infections
GB9604669D0 (en)	1996-03-05	1996-05-01	Ciba Geigy Ag	Chemical compounds
US5824669A (en)	1996-03-22	1998-10-20	Nitromed, Inc.	Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
DE69738254T2 (en)	1996-05-10	2008-08-14	Novozymes A/S	METHOD FOR PROVISION OF DNA SEQUENCES
US5856465A (en)	1996-05-24	1999-01-05	Polska Akademia Nauk Centrum Badan Molekularnych I Makromolekularnych	Compositions and methods for the synthesis of chirally pure organophosphorus nucleoside derivatives
WO2005121370A2 (en)	2004-06-03	2005-12-22	Isis Pharmaceuticals, Inc.	Oligomeric compounds that facilitate risc loading
US5898031A (en)	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
DE19622783A1 (en)	1996-06-07	1997-12-11	Hoechst Ag	Isolation of the biosynthetic genes for pseudo-oligosaccharides from Streptomyces glaucescens GLA.O and their use
EP0912767B1 (en)	1996-07-16	2006-09-13	Gen-Probe Incorporated	Methods for detecting and amplifying nucleic acid sequences using modified oligonucleotides having increased target specific tm
AU717387B2 (en)	1996-07-24	2000-03-23	Rolf H. Berg	Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
AU4156197A (en)	1996-08-21	1998-03-06	Hybridon, Inc.	Oligonucleotide prodrugs
US6056973A (en)	1996-10-11	2000-05-02	Sequus Pharmaceuticals, Inc.	Therapeutic liposome composition and method of preparation
GB9621522D0 (en)	1996-10-16	1996-12-04	Biocompatibles Ltd	Synthesis of phosphorus compounds
US6172209B1 (en)	1997-02-14	2001-01-09	Isis Pharmaceuticals Inc.	Aminooxy-modified oligonucleotides and methods for making same
US6639062B2 (en)	1997-02-14	2003-10-28	Isis Pharmaceuticals, Inc.	Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom
US6369237B1 (en)	1997-03-07	2002-04-09	President And Fellows Of Harvard College	DNA glycosylase inhibitors, and uses related thereto
US6015887A (en)	1997-04-11	2000-01-18	Isis Pharmaceuticals, Inc.	Chiral peptide nucleic acids and methods for preparing same
US6468983B2 (en)	1997-04-21	2002-10-22	The Cleveland Clinic Foundation	RNase L activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies
PL184612B1 (en)	1997-04-25	2002-11-29	Pan	Method of obtaining p-chiral analoques of nucleotides
AU745309B2 (en)	1997-05-28	2002-03-21	Peter E. Nielsen	Conjugated peptide nucleic acids having enhanced cellular uptake
BR9810946A (en)	1997-06-27	2000-09-26	Procter & Gamble	"cyclic acetals for fragrance"
AU8512598A (en)	1997-07-25	1999-02-16	Hybridon, Inc.	Oligonuclotides having 3' terminal stereospecific phosphorothioates
US6767739B2 (en)	2001-07-30	2004-07-27	Isis Pharmaceuticals Inc.	Antisense modulation of microsomal triglyceride transfer protein expression
GB9717158D0 (en)	1997-08-13	1997-10-22	King S College London	Solution synthesis of oligonucleotides and their phosphorothioate analogues
US6383808B1 (en)	2000-09-11	2002-05-07	Isis Pharmaceuticals, Inc.	Antisense inhibition of clusterin expression
US6750344B1 (en)	1997-09-05	2004-06-15	Isis Pharmaceuticals, Inc.	Amine compounds and combinatorial libraries comprising same
US6794499B2 (en)	1997-09-12	2004-09-21	Exiqon A/S	Oligonucleotide analogues
DE19741715A1 (en)	1997-09-22	1999-03-25	Hoechst Ag	New pentopyranosyl nucleoside compounds
US6232463B1 (en)	1997-10-09	2001-05-15	Isis Pharmaceuticals, Inc.	Substituted purines and oligonucleotide cross-linking
US6617438B1 (en)	1997-11-05	2003-09-09	Sirna Therapeutics, Inc.	Oligoribonucleotides with enzymatic activity
US6528640B1 (en)	1997-11-05	2003-03-04	Ribozyme Pharmaceuticals, Incorporated	Synthetic ribonucleic acids with RNAse activity
US6080543A (en)	1997-12-08	2000-06-27	E. & J. Gallo Winery	Detection of fungal pathogens
US6582936B1 (en)	1997-12-12	2003-06-24	The Regents Of The University Of California	Methods for making nucleic acids
US6248519B1 (en)	1998-03-11	2001-06-19	E & J Gallo Winery	Detection of fermentation-related microorganisms
US7045610B2 (en)	1998-04-03	2006-05-16	Epoch Biosciences, Inc.	Modified oligonucleotides for mismatch discrimination
JP2002513763A (en)	1998-05-06	2002-05-14	ユニバーシティオブアイオワリサーチファウンデーション	Methods for preventing and treating parasitic infections and related diseases using CPG oligonucleotides
EP1674574A1 (en)	1998-05-14	2006-06-28	Coley Pharmaceutical GmbH	Methods for Regulating Hematopoiesis using CpG-Oligonucleotides
US6242589B1 (en)	1998-07-14	2001-06-05	Isis Pharmaceuticals, Inc.	Phosphorothioate oligonucleotides having modified internucleoside linkages
US6867294B1 (en)	1998-07-14	2005-03-15	Isis Pharmaceuticals, Inc.	Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
EP1100807A1 (en)	1998-07-27	2001-05-23	University Of Iowa Research Foundation	STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS
CA2340174C (en)	1998-08-10	2011-01-04	Aquila Biopharmaceuticals, Inc.	Compositions of cpg and saponin adjuvants and methods thereof
WO2000023444A1 (en)	1998-10-21	2000-04-27	Abbott Laboratories	5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
US6995259B1 (en)	1998-10-23	2006-02-07	Sirna Therapeutics, Inc.	Method for the chemical synthesis of oligonucleotides
US6451524B1 (en)	1998-11-25	2002-09-17	Isis Pharmaceuticals, Inc.	Identification of disease predictive nucleic acids
AU1742600A (en)	1998-11-25	2000-06-13	Isis Pharmaceuticals, Inc.	Identification of disease predictive nucleic acids
DE69941223D1 (en)	1998-12-21	2009-09-17	Billig Fritz	CHEMICALLY MODIFIED ENZYMES WITH MULTIPLE CHARGED VARIATIONS
CA2702148C (en)	1999-01-06	2014-03-04	Genenews Inc.	Method of profiling gene expression in a human subject having an infectious disease
US6265172B1 (en)	1999-02-08	2001-07-24	University Of Kentucky	Diagnostic test and therapy for manganese superoxide dismutate (mNsod) associated diseases
US6121437A (en)	1999-03-16	2000-09-19	Isis Pharmaceuticals, Inc.	Phosphate and thiophosphate protecting groups
US6506594B1 (en)	1999-03-19	2003-01-14	Cornell Res Foundation Inc	Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
GB9907245D0 (en)	1999-03-29	1999-05-26	Goldsborough Andrew	Cleavage of nucleic acids from solid supports
JP3072345B1 (en)	1999-03-31	2000-07-31	農林水産省家畜衛生試験場長	Swine erysipelas recombinant subunit vaccine
US5998148A (en)	1999-04-08	1999-12-07	Isis Pharmaceuticals Inc.	Antisense modulation of microtubule-associated protein 4 expression
US6977245B2 (en)	1999-04-12	2005-12-20	The United States Of America As Represented By The Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
US6300069B1 (en)	1999-05-03	2001-10-09	Qiagen Gmbh	Generation and amplification of nucleic acids from ribonucleic acids
US6656730B1 (en)	1999-06-15	2003-12-02	Isis Pharmaceuticals, Inc.	Oligonucleotides conjugated to protein-binding drugs
US6271004B1 (en)	1999-06-25	2001-08-07	Display Systems Biotech A/S	Method for improved reverse transcription at high temperatures
US6066500A (en)	1999-06-25	2000-05-23	Isis Pharmaceuticals Inc.	Antisense modulation of Beta catenin expression
US6414135B1 (en)	1999-07-07	2002-07-02	Isis Pharmaceuticals, Inc.	C3′-methylene hydrogen phosphonate monomers and related compounds
US20030092647A1 (en)	2001-08-08	2003-05-15	Crooke Rosanne M.	Antisense modulation of cholesteryl ester transfer protein expression
US6147200A (en)	1999-08-19	2000-11-14	Isis Pharmaceuticals, Inc.	2'-O-acetamido modified monomers and oligomers
US7264932B2 (en)	1999-09-24	2007-09-04	Applera Corporation	Nuclease inhibitor cocktail
EP1700603A3 (en)	1999-09-25	2007-06-13	Coley Pharmaceutical GmbH	Immunostimulatory nucleic acids
WO2001022990A2 (en)	1999-09-27	2001-04-05	Coley Pharmaceutical Group, Inc.	Methods related to immunostimulatory nucleic acid-induced interferon
US6949520B1 (en)	1999-09-27	2005-09-27	Coley Pharmaceutical Group, Inc.	Methods related to immunostimulatory nucleic acid-induced interferon
US20020082227A1 (en)	1999-09-30	2002-06-27	Scott Henry	Use of oligonucleotides for inhibition of complement activation
IL148922A0 (en)	1999-10-06	2002-09-12	Quark Biotech Inc	Method for enrichment of natural antisense messenger rna
GB9924285D0 (en)	1999-10-14	1999-12-15	Avecia Ltd	Process
US20010055761A1 (en)	1999-10-29	2001-12-27	Agilent Technologies	Small scale dna synthesis using polymeric solid support with functionalized regions
FR2800750B1 (en)	1999-11-05	2003-01-31	Centre Nat Rech Scient	MEMBRANE PROTEINS CTL (CHOLINE TRANSPORTER LIKE) INVOLVED IN THE TRANSPORT OF CHOLINE
WO2001040515A1 (en)	1999-11-12	2001-06-07	Isis Pharmaceuticals, Inc.	Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6322985B1 (en)	1999-12-27	2001-11-27	Technion Research And Development Foundation Ltd.	Abundant, well distributed and hyperpolymorphic simple sequence repeats in prokaryote genomes and use of same for prokaryote classification and typing
US7501091B2 (en)	1999-12-30	2009-03-10	Smiths Detection Inc.	Sensors with improved properties
WO2001050349A1 (en)	1999-12-30	2001-07-12	Rutgers, The State University Of New Jersey	Electronic document customization and transformation utilizing user feedback
US6649750B1 (en)	2000-01-05	2003-11-18	Isis Pharmaceuticals, Inc.	Process for the preparation of oligonucleotide compounds
US6159697A (en)	2000-01-19	2000-12-12	Isis Pharmaceuticals, Inc.	Antisense modulation of Smad7 expression
US7585847B2 (en)	2000-02-03	2009-09-08	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for the treatment of asthma and allergy
US6495677B1 (en)	2000-02-15	2002-12-17	Kanda S. Ramasamy	Nucleoside compounds
EP1130091A3 (en)	2000-03-01	2001-11-14	Message Pharmaceuticals, Inc.	Bacterial RNaseP Proteins and their use in identifying antibacterial compounds
GB0004889D0 (en)	2000-03-01	2000-04-19	Avecia Ltd	Synthesis of oligonucleotides
EP1265840A2 (en)	2000-03-17	2002-12-18	Corixa Corporation	Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
PT1278728E (en)	2000-04-20	2004-10-29	Hoffmann La Roche	PYRROLIDINE AND PIPERIDINE DERIVATIVES AND THEIR USE IN TREATING NEURODEGENERATIVE DISTURBANCES
DE10019756A1 (en)	2000-04-20	2001-10-25	Bayer Ag	Process for the production of superabsorbent polymers from polyacrylonitriles
AU2001259706A1 (en)	2000-05-09	2001-11-20	Reliable Biopharmaceutical, Inc.	Polymeric compounds useful as prodrugs
US6492171B2 (en)	2000-05-16	2002-12-10	Isis Pharmaceuticals, Inc.	Antisense modulation of TERT expression
US6815542B2 (en)	2000-06-16	2004-11-09	Ribapharm, Inc.	Nucleoside compounds and uses thereof
JP3074398U (en)	2000-06-27	2001-01-12	ドンウーキヨンジュシクヘサ	Automotive interior type ozone generator
EP1307469B1 (en)	2000-08-03	2008-01-23	Boehringer Mannheim Gmbh	Nucleic acid binding compounds containing pyrazolo¬3,4-d pyrimidine analogues of purin-2,6-diamine and their uses
US6725412B1 (en)	2000-08-15	2004-04-20	Dolby Laboratories Licensing Corporation	Low latency data encoder
US6809195B1 (en)	2000-08-16	2004-10-26	Isis Pharmaceuticals, Inc.	Process for the preparation of oligonucleotides
US6559279B1 (en)	2000-09-08	2003-05-06	Isis Pharmaceuticals, Inc.	Process for preparing peptide derivatized oligomeric compounds
CA2419894A1 (en)	2000-09-15	2002-03-21	Coley Pharmaceutical Gmbh	Process for high throughput screening of cpg-based immuno-agonist/antagonist
EP1191097A1 (en)	2000-09-21	2002-03-27	Leids Universitair Medisch Centrum	Induction of exon skipping in eukaryotic cells
GB0024752D0 (en)	2000-10-10	2000-11-22	Univ Belfast	Oxidative halogenation of aromatic compounds
PL208755B1 (en)	2000-10-18	2011-06-30	Glaxosmithkline Biolog Sa	Vaccines
US6372492B1 (en)	2000-10-30	2002-04-16	Isis Pharmaceuticals, Inc.	Antisense modulation of talin expression
US6682889B1 (en)	2000-11-08	2004-01-27	Becton, Dickinson And Company	Amplification and detection of organisms of the Chlamydiaceae family
NL1016978C2 (en)	2000-12-22	2002-06-25	Robert Jan Colenbrander	Device and method for packaging and preparing food and method for manufacturing such a device.
WO2002057425A2 (en)	2001-01-22	2002-07-25	Merck & Co., Inc.	Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US8008459B2 (en)	2001-01-25	2011-08-30	Evolva Sa	Concatemers of differentially expressed multiple genes
DE60239386D1 (en)	2001-01-25	2011-04-21	Evolva Ltd	CELL LIBRARY
NZ526507A (en)	2001-01-26	2005-07-29	Commw Scient Ind Res Org	Methods and means for producing efficient silencing construct using recombinational cloning
US20050277133A1 (en)	2001-05-18	2005-12-15	Sirna Therapeutics, Inc.	RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US20030207804A1 (en)	2001-05-25	2003-11-06	Muthiah Manoharan	Modified peptide nucleic acids
GB0113523D0 (en)	2001-06-04	2001-07-25	Torotrak Dev Ltd	An Hydraulic control circuit for a continuosly variable transmission
US20030069410A1 (en)	2001-06-14	2003-04-10	Isis Pharmaceuticals, Inc.	Methods for preparing oligonucleotides having chiral phosphorothioate linkages
US20050019915A1 (en)	2001-06-21	2005-01-27	Bennett C. Frank	Antisense modulation of superoxide dismutase 1, soluble expression
CN1636015A (en)	2001-06-29	2005-07-06	希龙公司	HCV e1e2 vaccine compositions
CA2452458A1 (en)	2001-07-03	2003-01-16	Isis Pharmaceuticals, Inc.	Nuclease resistant chimeric oligonucleotides
US7205399B1 (en)	2001-07-06	2007-04-17	Sirna Therapeutics, Inc.	Methods and reagents for oligonucleotide synthesis
US6440739B1 (en)	2001-07-17	2002-08-27	Isis Pharmaceuticals, Inc.	Antisense modulation of glioma-associated oncogene-2 expression
US7425545B2 (en)	2001-07-25	2008-09-16	Isis Pharmaceuticals, Inc.	Modulation of C-reactive protein expression
US6455308B1 (en)	2001-08-01	2002-09-24	Isis Pharmaceuticals, Inc.	Antisense modulation of serum amyloid A4 expression
US7888324B2 (en)	2001-08-01	2011-02-15	Genzyme Corporation	Antisense modulation of apolipoprotein B expression
US7407943B2 (en)	2001-08-01	2008-08-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein B expression
US7227014B2 (en)	2001-08-07	2007-06-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein (a) expression
US7259150B2 (en)	2001-08-07	2007-08-21	Isis Pharmaceuticals, Inc.	Modulation of apolipoprotein (a) expression
WO2003020884A2 (en)	2001-08-14	2003-03-13	The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services	Method for rapid generation of mature dendritic cells
WO2003017930A2 (en)	2001-08-24	2003-03-06	Massachusetts Institute Of Technology	Reagents that facilitate the purification of compounds synthesized on a solid support
US7049122B2 (en)	2001-09-21	2006-05-23	Academia Sinica	Mutant-type lipases and applications thereof
US6933288B2 (en)	2002-02-04	2005-08-23	Isis Pharmaceuticals, Inc.	Pyranosyl cytosines: pharmaceutical formulations and methods
JP4348044B2 (en)	2002-02-12	2009-10-21	株式会社キラルジェン	Method for producing highly stereoregular dinucleoside phosphorothioates
US20030159938A1 (en)	2002-02-15	2003-08-28	George Hradil	Electroplating solution containing organic acid complexing agent
US20040149587A1 (en)	2002-02-15	2004-08-05	George Hradil	Electroplating solution containing organic acid complexing agent
US20050096284A1 (en)	2002-02-20	2005-05-05	Sirna Therapeutics, Inc.	RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US8232383B2 (en)	2002-02-20	2012-07-31	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
EP1485396A2 (en)	2002-02-28	2004-12-15	Biota, Inc.	Nucleoside 5'-monophosphate mimics and their prodrugs
JP2005525358A (en)	2002-02-28	2005-08-25	ビオタインコーポレーティッド	Nucleotide mimetics and their prodrugs
US7288376B2 (en)	2002-03-22	2007-10-30	Council Of Scientific And Industrial Research	Method of detection of SP-A2 gene variants useful for prediction of predisposition to aspergillosis
US20040102394A1 (en)	2002-11-23	2004-05-27	Isis Pharmaceuticals Inc.	Modulation of huntingtin interacting protein 2 expression
US7247621B2 (en)	2002-04-30	2007-07-24	Valeant Research & Development	Antiviral phosphonate compounds and methods therefor
WO2003097662A1 (en)	2002-05-15	2003-11-27	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein b expression
US20040014957A1 (en)	2002-05-24	2004-01-22	Anne Eldrup	Oligonucleotides having modified nucleoside units
US20040014108A1 (en)	2002-05-24	2004-01-22	Eldrup Anne B.	Oligonucleotides having modified nucleoside units
US7507808B2 (en)	2002-12-12	2009-03-24	Isis Pharmaceuticals, Inc.	Modulation of endothelial lipase expression
WO2003106477A1 (en)	2002-06-01	2003-12-24	Isis Pharmaceuticals, Inc.	Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
US20040005338A1 (en)	2002-06-20	2004-01-08	Cytos Biotechnology Ag	Packaged virus-like particles for use as adjuvants: method of preparation and use
WO2004003228A1 (en)	2002-07-01	2004-01-08	Unisearch Limited	Genotyping method
EP2314690A1 (en)	2002-07-10	2011-04-27	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	RNA-interference by single-stranded RNA molecules
US20040023905A1 (en)	2002-07-31	2004-02-05	Isis Pharmaceuticals Inc.	Antisense modulation of LAR expression
US20050255086A1 (en)	2002-08-05	2005-11-17	Davidson Beverly L	Nucleic acid silencing of Huntington's Disease gene
US20050042646A1 (en)	2002-08-05	2005-02-24	Davidson Beverly L.	RNA interference suppresion of neurodegenerative diseases and methods of use thereof
US20080274989A1 (en)	2002-08-05	2008-11-06	University Of Iowa Research Foundation	Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
US8729036B2 (en)	2002-08-07	2014-05-20	University Of Massachusetts	Compositions for RNA interference and methods of use thereof
AU2003259735A1 (en)	2002-08-08	2004-02-25	Sirna Therapeutics, Inc.	Small-mer compositions and methods of use
AR040996A1 (en)	2002-08-19	2005-04-27	Coley Pharm Group Inc	IMMUNE STIMULATING NUCLEIC ACIDS
US7414116B2 (en)	2002-08-23	2008-08-19	Illumina Cambridge Limited	Labelled nucleotides
BR0314236A (en)	2002-09-13	2005-08-09	Replicor Inc	Oligonucleotide formulation, pharmaceutical composition, kit, antiviral compound, preparation of oligonucleotide and methods for selection of an antiviral oligonucleotide for use as an antiviral agent, for prophylaxis or treatment of a viral infection in a patient, for prophylactic treatment of cancer caused by oncoviruses. for identifying a compound that alters the binding of an oligonucleotide to at least one viral component, for purifying oligonucleotide binding to at least one viral component and for enriching oligonucleotides from an oligonucleotide cluster
US7030230B2 (en)	2002-10-25	2006-04-18	Isis Pharmaceuticals, Inc.	Process of purifying phosphoramidites
SI2241325T1 (en)	2002-10-29	2012-05-31	Coley Pharm Group Inc	Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
AU2003291721A1 (en)	2002-11-05	2004-06-03	Isis Pharmaceuticals, Inc.	Phosphorous-linked oligomeric compounds and their use in gene modulation
AU2003290597A1 (en)	2002-11-05	2004-06-03	Isis Pharmaceuticals, Inc.	Modified oligonucleotides for use in rna interference
AU2003291753B2 (en)	2002-11-05	2010-07-08	Isis Pharmaceuticals, Inc.	Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
WO2004044141A2 (en)	2002-11-05	2004-05-27	Isis Pharmaceuticals, Inc.	Conjugated oligomeric compounds and their use in gene modulation
US7381527B2 (en)	2002-11-06	2008-06-03	Council Of Scientific And Industrial Research	Method of detection of SP-A2 gene variants
US7511131B2 (en)	2002-11-13	2009-03-31	Genzyme Corporation	Antisense modulation of apolipoprotein B expression
EP2336318B1 (en)	2002-11-13	2013-04-24	Genzyme Corporation	Antisense modulation of apolipoprotein b expression
DK2284266T3 (en)	2002-11-14	2014-01-13	Thermo Fisher Scient Biosciences Inc	SIRNA MOLECULE MOD TP53
WO2004080466A1 (en)	2003-03-07	2004-09-23	Ribapharm Inc.	Cytidine analogs and methods of use
WO2004080406A2 (en)	2003-03-07	2004-09-23	Alnylam Pharmaceuticals	Therapeutic compositions
WO2004083432A1 (en)	2003-03-21	2004-09-30	Academisch Ziekenhuis Leiden	Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
GB0306657D0 (en)	2003-03-24	2003-04-30	Avecia Ltd	Process and compounds
AU2004224761A1 (en)	2003-03-26	2004-10-07	Cytos Biotechnology Ag	HIV-peptide-carrier-conjugates
US7537767B2 (en)	2003-03-26	2009-05-26	Cytis Biotechnology Ag	Melan-A- carrier conjugates
ITRM20030149A1 (en)	2003-04-02	2004-10-03	Giuliani Spa	ANTISENSE OLIGONUCLEOTIDES (ODN) FOR SMAD7 AND THEIR USE IN THE MEDICAL FIELD
US7598227B2 (en)	2003-04-16	2009-10-06	Isis Pharmaceuticals Inc.	Modulation of apolipoprotein C-III expression
WO2004096233A2 (en)	2003-04-25	2004-11-11	Gilead Sciences, Inc.	Nucleoside phosphonate conjugates
US7407965B2 (en)	2003-04-25	2008-08-05	Gilead Sciences, Inc.	Phosphonate analogs for treating metabolic diseases
AU2004233989A1 (en)	2003-04-25	2004-11-11	Gilead Sciences, Inc.	Anti-cancer phosphonate analogs
US7452901B2 (en)	2003-04-25	2008-11-18	Gilead Sciences, Inc.	Anti-cancer phosphonate analogs
US7470724B2 (en)	2003-04-25	2008-12-30	Gilead Sciences, Inc.	Phosphonate compounds having immuno-modulatory activity
US20050261237A1 (en)	2003-04-25	2005-11-24	Boojamra Constantine G	Nucleoside phosphonate analogs
JP5069463B2 (en)	2003-04-25	2012-11-07	ギリアードサイエンシーズ，インコーポレイテッド	Antiviral phosphonate analogues
CN101410120A (en)	2003-04-25	2009-04-15	吉里德科学公司	Anti-inflammatory phosphonate compounds
US7432261B2 (en)	2003-04-25	2008-10-07	Gilead Sciences, Inc.	Anti-inflammatory phosphonate compounds
WO2005002626A2 (en)	2003-04-25	2005-01-13	Gilead Sciences, Inc.	Therapeutic phosphonate compounds
US20090247488A1 (en)	2003-04-25	2009-10-01	Carina Cannizzaro	Anti-inflammatory phosphonate compounds
US7045306B2 (en)	2003-04-28	2006-05-16	The General Hospital Corporation	Method for identifying compounds in vitro that modulate the dysregulation of transcription of transcription mediated by mutant huntingtin protein
US7214491B2 (en)	2003-05-07	2007-05-08	E. I. Du Pont De Nemours And Company	Δ-12 desaturase gene suitable for altering levels of polyunsaturated fatty acids in oleaginous yeasts
US7589189B2 (en)	2003-05-14	2009-09-15	Japan Science And Technology Agency	Inhibition of the expression of huntingtin gene
BRPI0410886A (en)	2003-06-03	2006-07-04	Isis Pharmaceuticals Inc	double stranded compound, pharmaceutical composition, pharmaceutically acceptable salt, methods of modifying human survivin-encoding nucleic acid, inhibiting suvivin expression in cells or tissues, and treating a condition associated with suvivin expression or overexpression, and single stranded RNA oligonucleotide
AU2004257149A1 (en)	2003-06-20	2005-01-27	Coley Pharmaceutical Gmbh	Small molecule toll-like receptor (TLR) antagonists
US7683036B2 (en)	2003-07-31	2010-03-23	Regulus Therapeutics Inc.	Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
JP2005089441A (en) *	2003-08-08	2005-04-07	Toudai Tlo Ltd	Manufacturing method of highly stereoregular phosphorus atom-modified nucleotide analogue
JP2011088935A (en)	2003-08-08	2011-05-06	Chiralgen Ltd	Optically-active nucleoside 3'-phosphoroamidite for production of phosphorus atom modified nucleotide analog
US7825235B2 (en)	2003-08-18	2010-11-02	Isis Pharmaceuticals, Inc.	Modulation of diacylglycerol acyltransferase 2 expression
JP2007502779A (en)	2003-08-21	2007-02-15	グリフィスユニバーシティ	New sulfenamide
EP1664071A1 (en)	2003-08-21	2006-06-07	Griffith University	Novel sulfenamide oxides
KR20060123707A (en)	2003-08-27	2006-12-04	바이오타, 인코포레이티드	Novel trinucleosides or nucleotides as therapeutic agents
EP1661905B9 (en)	2003-08-28	2012-12-19	IMANISHI, Takeshi	Novel artificial nucleic acids of n-o bond crosslinkage type
WO2005028494A1 (en)	2003-09-02	2005-03-31	Takeshi Wada	Process for producing 5'-phosphitylated monomer and h-phosphonate oligonucleotide derivative
JP4580870B2 (en)	2003-09-02	2010-11-17	株式会社キラルジェン	Method for producing ribonucleotide or ribonucleotide derivative
EP3342425B1 (en)	2003-09-09	2019-12-18	Geron Corporation	Modified oligonucleotides for telomerase inhibition
US20050053981A1 (en)	2003-09-09	2005-03-10	Swayze Eric E.	Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
US20050074801A1 (en)	2003-09-09	2005-04-07	Monia Brett P.	Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry
EP2821085B1 (en)	2003-09-12	2020-04-29	University of Massachusetts	Rna interference for the treatment of gain-of-function disorders
US8680063B2 (en)	2003-09-12	2014-03-25	University Of Massachusetts	RNA interference for the treatment of gain-of-function disorders
GB0323968D0 (en)	2003-10-13	2003-11-19	Glaxosmithkline Biolog Sa	Immunogenic compositions
EP1678303A2 (en)	2003-10-30	2006-07-12	Coley Pharmaceutical GmbH	C-class oligonucleotide analogs with enhanced immunostimulatory potency
US20050239102A1 (en)	2003-10-31	2005-10-27	Verdine Gregory L	Nucleic acid binding oligonucleotides
US7846436B2 (en)	2003-11-28	2010-12-07	Chemgenes Corporation	Oligonucleotides and related compounds
AU2003300239A1 (en)	2003-12-29	2005-07-21	Galapagos Genomics N.V.	Modulators of bone homeostasis identified in a high-throughput screen
WO2005070859A1 (en)	2004-01-27	2005-08-04	Takeshi Wada	Fluorous supports and processes for production of oligonucleotide derivatives with the same
US20050176045A1 (en)	2004-02-06	2005-08-11	Dharmacon, Inc.	SNP discriminatory siRNA
EP1725250A2 (en)	2004-02-18	2006-11-29	Frutarom Ltd.	Method for the preparation of peptide-oligonucleotide conjugates
JP3976742B2 (en)	2004-02-27	2007-09-19	江守商事株式会社	Immunostimulatory oligonucleotides that induce interferon alpha
WO2005085272A1 (en)	2004-03-05	2005-09-15	Takeshi Wada	Boranophosphate monomer and process for producing oligonucleotide derivative therefrom
WO2005092909A1 (en) *	2004-03-25	2005-10-06	Toudai Tlo, Ltd.	Processes for producing ribonucleotide analogue with high stereoregularity and deoxyribonucleotide analogue
US20050244869A1 (en)	2004-04-05	2005-11-03	Brown-Driver Vickie L	Modulation of transthyretin expression
EP2540734B1 (en)	2004-04-05	2016-03-30	Alnylam Pharmaceuticals, Inc.	Process and reagents for oligonucleotide synthesis and purification
TWI350168B (en)	2004-05-07	2011-10-11	Incyte Corp	Amido compounds and their use as pharmaceuticals
WO2005116268A2 (en)	2004-05-27	2005-12-08	The Government Of The United States Of America As Represented By The Secretary, Department Of Health	Differential expression of molecules associated with acute stroke
US7759318B1 (en)	2004-05-28	2010-07-20	Isis Pharmaceuticals, Inc.	Identification of novel pathways, genes and promoter motifs regulating adipogenesis
ES2361325T3 (en)	2004-06-28	2011-06-16	The University Of Western Australia	OLIGONUCLEÓTIDOS ANTISENTIDO TO INDUCE THE OMISSION OF EXON AND METHODS OF USE OF THE SAME.
DK1786472T3 (en)	2004-08-10	2013-04-15	Genzyme Corp	Antisense modulation of apolipoprotein B expression
ES2386709T3 (en)	2004-08-26	2012-08-27	Nippon Shinyaku Co., Ltd.	Phosphoramidite compound and method to produce an oligo-RNA
JP2008512097A (en)	2004-09-07	2008-04-24	アーケミックスコーポレイション	Aptamer medicinal chemistry
US7884086B2 (en)	2004-09-08	2011-02-08	Isis Pharmaceuticals, Inc.	Conjugates for use in hepatocyte free uptake assays
WO2006031461A2 (en)	2004-09-09	2006-03-23	Isis Pharmaceuticals, Inc.	Pyrrolidinyl groups for attaching conjugates to oligomeric compounds
AU2005286738A1 (en)	2004-09-17	2006-03-30	Isis Pharmaceuticals, Inc.	Enhanced antisense oligonucleotides
JP4944034B2 (en)	2004-10-13	2012-05-30	アイシスファーマシューティカルズ，インコーポレーテッド	Antisense regulation of PTP1B expression
US9120774B2 (en)	2004-11-03	2015-09-01	University Of Kansas	Novobiocin analogues having modified sugar moieties
WO2010096650A1 (en)	2009-02-20	2010-08-26	University Of Kansas	Novobiocin analogues having modified sugar moieties
US8212012B2 (en)	2004-11-03	2012-07-03	University Of Kansas	Novobiocin analogues having modified sugar moieties
CA2585091C (en)	2004-11-03	2016-07-19	University Of Kansas	Novobiocin analogues as anticancer agents
US7622451B2 (en)	2004-11-03	2009-11-24	University Of Kansas	Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
US8212011B2 (en)	2004-11-03	2012-07-03	University Of Kansas	Novobiocin analogues
KR100721928B1 (en)	2004-11-05	2007-05-28	주식회사 바이오씨에스	Pharmaceutical composition for treating or preventing dermatitis comprising CpG oligodeoxynucleotide
EP1657307A1 (en)	2004-11-16	2006-05-17	Immunotech S.A.	Oligonucleotides that induce the secretion of GM-CSF
WO2006063252A2 (en)	2004-12-09	2006-06-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering rnas
US9809824B2 (en)	2004-12-13	2017-11-07	The United States Of America, Represented By The Secretary, Department Of Health And Human Services	CpG oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
WO2006066260A2 (en)	2004-12-17	2006-06-22	Thiosense, Inc.	Compositions of and methods for producing phosphorus-chiral monomers and oligomers
US20070099851A1 (en)	2004-12-30	2007-05-03	Linn Gregory S	Stable analogues of ribose-1-phosphate and methods for treating diabetes and other metabolic disorders
US20060183763A1 (en)	2004-12-31	2006-08-17	Pfizer Inc	Novel pyrrolidyl derivatives of heteroaromatic compounds
WO2006080596A1 (en)	2005-01-28	2006-08-03	Hyung-Joo Kwon	Oligonucleotides derived from mycobacterium for stimulating immune function, treating immune-related diseases, atopic dermatitis and/or protecting normal immune cell
EP1851314A2 (en)	2005-02-24	2007-11-07	Coley Pharmaceutical Group, Inc.	Immunostimulatory oligonucleotides
JP5242375B2 (en)	2005-04-01	2013-07-24	ザレゲントスオブザユニバーシティオブカリフォルニア	Phosphono-pent-2-en-1-yl nucleosides and analogs
BRPI0611452A2 (en)	2005-05-05	2010-09-08	Antisense Pharma Gmbh	oligonucleotide dosage
WO2006121960A2 (en)	2005-05-06	2006-11-16	Medtronic, Inc.	Methods and sequences to suppress primate huntington gene expression
US7902352B2 (en)	2005-05-06	2011-03-08	Medtronic, Inc.	Isolated nucleic acid duplex for reducing huntington gene expression
EP2548560B1 (en)	2005-06-23	2015-06-03	Isis Pharmaceuticals, Inc.	Compositions and methods for modulation of SMN2 splicing
US9133517B2 (en)	2005-06-28	2015-09-15	Medtronics, Inc.	Methods and sequences to preferentially suppress expression of mutated huntingtin
WO2007002904A2 (en)	2005-06-28	2007-01-04	Medtronic, Inc.	Methods and sequences to preferentially suppress expression of mutated huntingtin
EP1948600B1 (en)	2005-07-05	2014-04-16	The President & Fellows Of Harvard College	Liver targeted conjugates
JP4984634B2 (en)	2005-07-21	2012-07-25	ソニー株式会社	Physical information acquisition method and physical information acquisition device
SI1924252T1 (en)	2005-07-28	2011-12-30	Id Fish Technology Inc	Method for improving cell permeability to foreign particles
ATE494372T1 (en)	2005-08-29	2011-01-15	Regulus Therapeutics Inc	METHOD FOR MIR-122A MODULATION
EP1937312B1 (en)	2005-08-30	2016-06-29	Ionis Pharmaceuticals, Inc.	Chimeric oligomeric compounds for modulation of splicing
US7700567B2 (en)	2005-09-29	2010-04-20	Supergen, Inc.	Oligonucleotide analogues incorporating 5-aza-cytosine therein
US20070077993A1 (en)	2005-09-30	2007-04-05	Midgley Timothy M	Method and apparatus for collecting user game play data and crediting users in a gaming environment
KR101455081B1 (en)	2005-10-12	2014-10-27	이데라 파마슈티칼즈, 인코포레이티드	Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
US9308252B2 (en)	2005-10-27	2016-04-12	Cook Biotech, Inc.	Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
CN101466834B (en)	2005-10-28	2013-09-25	东曹株式会社	Method for production of carotenoid-synthesizing microorganism and method for production of carotenoid
JP5111385B2 (en)	2005-10-28	2013-01-09	アルナイラムファーマシューティカルズ，インコーポレイテッド	Composition and method for suppressing expression of huntingtin gene
KR20080075107A (en)	2005-11-11	2008-08-14	화이자 인코포레이티드	Combinations and methods of using an immunomodulatory oligodeoxynucleotide
WO2007064291A1 (en)	2005-11-30	2007-06-07	Jyoti Chattopadhyaya	Method and compounds for rna synthesis
WO2007064954A2 (en)	2005-12-02	2007-06-07	Isis Pharmaceuticals, Inc.	Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents
US8076303B2 (en)	2005-12-13	2011-12-13	Spring Bank Pharmaceuticals, Inc.	Nucleotide and oligonucleotide prodrugs
DK1979356T3 (en)	2005-12-21	2013-11-18	Pfizer Prod Inc	CARBONYLAMINOPYRROLOPYRAZOLES, POWERFUL KINASE INHIBITORS
EP2428227B1 (en)	2006-01-26	2016-06-22	Ionis Pharmaceuticals, Inc.	Compositions and their uses directed to Huntingtin
DE602007009487D1 (en)	2006-01-27	2010-11-11	Isis Pharmaceutical Inc	6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGUE
EP1991678B2 (en)	2006-02-15	2020-07-15	Rechtsanwalt Thomas Beck	Compositions and methods for oligonucleotide formulations
JP4713514B2 (en)	2006-02-20	2011-06-29	エフ．ホフマン−ラロシュアーゲー	Improved labeling reagent
US8383660B2 (en)	2006-03-10	2013-02-26	Pfizer Inc.	Dibenzyl amine compounds and derivatives
JP2009533022A (en)	2006-03-31	2009-09-17	アプライドバイオシステムズ，エルエルシー	Useful reagents for the synthesis of rhodamine-labeled oligonucleotides
EP2010679A2 (en)	2006-04-06	2009-01-07	Ibis Biosciences, Inc.	Compositions for the use in identification of fungi
AU2007242883B2 (en)	2006-04-20	2012-09-27	F. Hoffmann-La Roche Ag	Diazepan derivatives modulators of chemokine receptors
US8206923B2 (en)	2006-04-24	2012-06-26	Elvira Garza Gonzalez	Method for detection and multiple, simultaneous quantification of pathogens by means of real-time polymerase chain reaction
US20130129752A1 (en)	2006-04-25	2013-05-23	Immune Disease Institute, Inc.	Targeted delivery to leukocytes using protein carriers
GB0608838D0 (en)	2006-05-04	2006-06-14	Novartis Ag	Organic compounds
US20090292006A1 (en)	2006-05-05	2009-11-26	Sanjay Bhanot	Compounds and methods for modulating expression of dgat2
WO2007131232A2 (en)	2006-05-05	2007-11-15	Isis Pharmaceuticals, Inc.	Compositions and their uses directed to ptpr alpha
US20090012120A1 (en)	2006-05-10	2009-01-08	Board Of Trustees Of Michigan State University	Synthesis of N-heterocycles, beta-amino acids, and allyl amines via aza-payne mediated reaction of ylides and hydroxy aziridines
AU2007249349B2 (en)	2006-05-11	2012-03-08	Isis Pharmaceuticals, Inc.	5'-Modified bicyclic nucleic acid analogs
US7666854B2 (en)	2006-05-11	2010-02-23	Isis Pharmaceuticals, Inc.	Bis-modified bicyclic nucleic acid analogs
EP2034015B1 (en)	2006-05-31	2012-07-11	Toray Industries, Inc.	Immunostimulatory oligonucleotide and pharmaceutical application thereof
US8097596B2 (en)	2006-06-30	2012-01-17	Lakewood-Amedex, Inc.	Compositions and methods for the treatment of muscle wasting
EP2046993A4 (en)	2006-07-07	2010-11-17	Univ Massachusetts	Rna silencing compositions and methods for the treatment of huntington's disease
CA2659103C (en)	2006-07-12	2019-05-21	The Regents Of The University Of California	Transducible delivery of nucleic acids by reversible phosphotriester charge neutralization protecting groups
US7666888B2 (en)	2006-07-20	2010-02-23	Amgen Inc.	Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1
GB0614947D0 (en)	2006-07-27	2006-09-06	Isis Innovation	Epitope reduction therapy
WO2008017081A1 (en)	2006-08-04	2008-02-07	Isis Pharmaceuticals, Inc.	Compositions and methods for the modulation of jnk proteins
AT504194B1 (en)	2006-09-07	2008-07-15	Oesterr Rotes Kreuz	BACTERIA DETECTION
US8138330B2 (en)	2006-09-11	2012-03-20	Sigma-Aldrich Co. Llc	Process for the synthesis of oligonucleotides
KR101251707B1 (en)	2006-09-27	2013-04-11	콜리 파마슈티칼 게엠베하	CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity
EP2410054B2 (en)	2006-10-18	2019-12-11	Ionis Pharmaceuticals, Inc.	Antisense compounds
CA2667816A1 (en)	2006-10-23	2008-05-02	Irm Llc	Compositions and methods for inhibiting cathepsin proteases
EP2104738A2 (en)	2006-10-26	2009-09-30	Coley Pharmaceuticals GmbH	Oligoribonucleotides and uses thereof
FR2908414B1 (en)	2006-11-13	2012-01-20	Centre Nat Rech Scient	IMMOBILIZATION OF MEMBRANE PROTEINS ON A SUPPORT THROUGH AN AMPHIPHILE MOLECULE
US8754107B2 (en)	2006-11-17	2014-06-17	Abbvie Inc.	Aminopyrrolidines as chemokine receptor antagonists
EP2102340A2 (en)	2006-11-27	2009-09-23	Isis Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia
US8093222B2 (en)	2006-11-27	2012-01-10	Isis Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia
US7884197B2 (en)	2006-12-12	2011-02-08	Idera Pharmaceuticals, Inc.	Synthetic agonists of TLR9
UY30892A1 (en)	2007-02-07	2008-09-02	Smithkline Beckman Corp	AKT ACTIVITY INHIBITORS
WO2008101157A1 (en)	2007-02-15	2008-08-21	Isis Pharmaceuticals, Inc.	5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
KR20090128494A (en)	2007-03-24	2009-12-15	겐자임 코포레이션	Administering antisense oligonucleotides complementary to human apolipoprotein b
US7960353B2 (en)	2007-05-10	2011-06-14	University Of Kansas	Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
JP5646320B2 (en)	2007-05-11	2014-12-24	アダイニクス，インコーポレイテッド	Gene expression and pain
CA2688008A1 (en)	2007-05-24	2008-11-27	Kyorin Pharmaceutical Co., Ltd.	Mutilin derivative having heterocyclic aromatic ring carboxylic acid structure in substituent at 14-position
GB0710186D0 (en)	2007-05-29	2007-07-04	Texas Instr Denmark	PWM loop with minimum allasing error property
US8278425B2 (en)	2007-05-30	2012-10-02	Isis Pharmaceuticals, Inc.	N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
NZ581364A (en)	2007-06-05	2011-10-28	Nsab Af Neurosearch Sweden Ab	Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
ES2386492T3 (en)	2007-06-08	2012-08-21	Isis Pharmaceuticals, Inc.	Carbocyclic bicyclic nucleic acid analogs
US20100298280A1 (en)	2007-06-13	2010-11-25	Petra Kioschis-Schneider	Compounds for the Modulation of Huntingtin Aggregation, Methods and Means for Identifying Such Compounds
EP2014769B1 (en)	2007-06-18	2010-03-31	Commissariat à l'Energie Atomique	Reversible siRNAa-based silencing of mutated and endogenous wild-type huntingtin gene and its application for the treatment of Huntington's disease
GB0712494D0 (en)	2007-06-27	2007-08-08	Isis Innovation	Substrate reduction therapy
AU2008272918B2 (en)	2007-07-05	2012-09-13	Isis Pharmaceuticals, Inc.	6-disubstituted bicyclic nucleic acid analogs
CN102921003B (en)	2007-07-09	2014-11-26	艾德拉药物股份有限公司	Stabilized immune modulatory RNA (SIMRA) compounds
TWI413530B (en)	2007-07-20	2013-11-01	Kao Corp	Organopolysiloxane
AU2008281281A1 (en)	2007-07-31	2009-02-05	University Of Saskatchewan	Genetic variation in Pro-Melanin-Concentrating Hormone gene affects carcass traits in cattle
US7812003B2 (en)	2007-08-02	2010-10-12	Safe Stephen H	Antisense microRNA and uses therefor
US8853375B2 (en)	2007-08-15	2014-10-07	Idera Pharmaceuticals, Inc.	Toll like receptor modulators
RU2501803C2 (en)	2007-10-01	2013-12-20	Айзис Фармасьютикалз, Инк.	Compositions and methods of modulation of expression of receptor of growth factor of fibroblasts 4 (fgfr4)
KR100886139B1 (en)	2007-11-13	2009-02-27	주식회사 삼천리제약	Method for preparing oligonucleotide
TW200930375A (en)	2007-12-21	2009-07-16	Exelixis Inc	Benzofuropyrimidinones
TWI340765B (en)	2007-12-26	2011-04-21	Ind Tech Res Inst	Oligonucleotide sequences and dna chip for identifying filamentous microorganisms and the identification method thereof
US20100309376A1 (en)	2008-01-15	2010-12-09	Yungchun Lei	Multimedia Presenting System, Multimedia Processing Apparatus Thereof, and Method for Presenting Video and Audio Signals
WO2009089659A1 (en)	2008-01-18	2009-07-23	Shanghai Targetdrug Co., Ltd.	Pyrollidine-based compounds
EP2240768A1 (en)	2008-02-04	2010-10-20	Galapagos N.V.	Target sequences and methods to identify the same, useful in treatment of neurodegenerative diseases
JP2009190983A (en)	2008-02-12	2009-08-27	Tokyo Institute Of Technology	Oligonucleotide derivative
EP2282744B1 (en)	2008-03-21	2018-01-17	Ionis Pharmaceuticals, Inc.	Oligomeric compounds comprising tricyclic nucleosides and methods for their use
WO2009120878A2 (en)	2008-03-26	2009-10-01	Alnylam Pharmaceuticals, Inc.	Non-natural ribonucleotides, and methods of use thereof
KR101927905B1 (en)	2008-04-03	2018-12-11	스프링 뱅크 파마슈티칼스, 인크.	Compositions and methods for treating viral infections
US8350022B2 (en)	2008-04-04	2013-01-08	Universitaet Hamburg	Method for the stereoselective synthesis of phosphorus compounds
US9290534B2 (en)	2008-04-04	2016-03-22	Ionis Pharmaceuticals, Inc.	Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleoside
US8679750B2 (en)	2008-05-09	2014-03-25	The University Of British Columbia	Methods and compositions for the treatment of Huntington'S disease
WO2009135322A1 (en)	2008-05-09	2009-11-12	The Universtity Of British Columbia	Methods and compositions for the treatment of huntington's disease
AU2009246169B2 (en)	2008-05-15	2015-01-22	Dynavax Technologies Corporation	Long term disease modification using immunostimulatory oligonucleotides
US8541387B2 (en)	2008-05-22	2013-09-24	Isis Pharmaceuticals, Inc.	Modulation of SMRT expression
WO2009143391A2 (en)	2008-05-22	2009-11-26	Isis Pharmaceuticals, Inc	Methods for modulation expression of creb
EP2291200A4 (en)	2008-05-22	2012-05-30	Isis Pharmaceuticals Inc	Methods for modulating expression of rbp4
WO2009148605A2 (en)	2008-06-04	2009-12-10	Isis Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia
AU2009266806A1 (en) *	2008-07-03	2010-01-07	Exelixis Inc.	CDK modulators
US8410070B2 (en)	2008-09-12	2013-04-02	University Of Louisville Research Foundation, Inc.	Compositions and methods for treating cancer, inhibiting proliferation, and inducing cell death
US8163707B2 (en)	2008-09-15	2012-04-24	Enanta Pharmaceuticals, Inc.	4′-allene-substituted nucleoside derivatives
CN102196740A (en) *	2008-09-22	2011-09-21	戴曼加拿大采集无限责任公司	Suitcase with integrated pull-out carrier
US8691971B2 (en)	2008-09-23	2014-04-08	Scott G. Petersen	Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating RNA interference
US8604192B2 (en)	2008-09-24	2013-12-10	Isis Pharmaceuticals, Inc.	Cyclohexenyl nucleic acids analogs
WO2010036698A1 (en)	2008-09-24	2010-04-01	Isis Pharmaceuticals, Inc.	Substituted alpha-l-bicyclic nucleosides
AU2009302385B2 (en)	2008-10-07	2015-12-03	President And Fellows Of Harvard College	Telomerase inhibitors and methods of use thereof
AU2009308380B2 (en)	2008-10-22	2015-05-28	Suzhou Ribo Life Science Co., Ltd.	Methods for treating eye disorders
EP2358398A2 (en)	2008-10-24	2011-08-24	Isis Pharmaceuticals, Inc.	Oligomeric compounds and methods
AU2009308217B2 (en)	2008-10-24	2016-01-21	Ionis Pharmaceuticals, Inc.	5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom
EP2370451B1 (en)	2008-12-02	2016-11-16	Wave Life Sciences Japan, Inc.	Method for the synthesis of phosphorus atom modified nucleic acids
JP2012513450A (en)	2008-12-23	2012-06-14	ギリンダス・アメリカ・インコーポレイテッド	Sulfurizing agents and their use to synthesize oligonucleotides
WO2010080953A1 (en)	2009-01-08	2010-07-15	Isis Pharmaceuticals, Inc.	Transgenic murine model of human lipoprotein metabolism, hypercholesterolemia and cardiovascular disease
KR20100087540A (en)	2009-01-28	2010-08-05	삼성전자주식회사	Ink composition for inkjet recording
US20120264806A1 (en)	2009-02-06	2012-10-18	Bennett C Frank	Oligomeric compounds and excipients
JP2012517226A (en)	2009-02-10	2012-08-02	イデラファーマシューティカルズインコーポレイテッド	Synthetic RNA-based agonists of TLR7
EP3424939A1 (en)	2009-03-02	2019-01-09	Alnylam Pharmaceuticals Inc.	Nucleic acid chemical modifications
WO2010107838A1 (en)	2009-03-16	2010-09-23	Isis Pharmaceuticals, Inc.	Targeting apolipoprotein b for the reduction of apolipoprotein c-iii
WO2010113937A1 (en)	2009-03-31	2010-10-07	武田薬品工業株式会社	Process for producing nucleoside
US8987222B2 (en)	2009-04-08	2015-03-24	University Of Massachusetts	Single nucleotide polymorphism (SNP) targeting therapies for the treatment of huntington'S disease
US20120156138A1 (en)	2009-04-14	2012-06-21	Smith Larry J	Methods and Compositions for the Treatment of Medical Conditions Involving Cellular Reprogramming
WO2010129853A2 (en)	2009-05-07	2010-11-11	The Regents Of The University Of California	TRANSDUCIBLE DELIVERY OF NUCLEIC ACIDS USING MODIFIED dsRNA BINDING DOMAINS
US20120142763A1 (en)	2009-06-01	2012-06-07	The Regents Of The University Of California	Nucleic acid delivery compositions and methods of use thereof
HUE031051T2 (en)	2009-06-05	2017-06-28	Infectious Disease Res Inst	Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them
PL3305302T3 (en)	2009-06-17	2019-02-28	Biogen Ma Inc.	Compositions and methods for modulation of smn2 splicing in a subject
JP5670097B2 (en)	2009-06-19	2015-02-18	花王株式会社	Two-layer separated hair cosmetic
EP2447273A4 (en)	2009-06-23	2013-06-19	Takeda Pharmaceutical	Method for synthesizing nucleic acid
KR101885383B1 (en)	2009-07-06	2018-08-03	웨이브 라이프 사이언시스 리미티드	Novel nucleic acid prodrugs and methods of use thereof
US8329024B2 (en)	2009-07-06	2012-12-11	Ada Technologies, Inc.	Electrochemical device and method for long-term measurement of hypohalites
WO2011005860A2 (en)	2009-07-07	2011-01-13	Alnylam Pharmaceuticals, Inc.	5' phosphate mimics
WO2011005942A2 (en)	2009-07-08	2011-01-13	Idera Pharmaceuticals, Inc.	Oligonucleotide-based compounds as inhibitors of toll-like receptors
WO2011010706A1 (en)	2009-07-23	2011-01-27	武田薬品工業株式会社	Fgf21 cis-element binding substance
WO2011015572A1 (en)	2009-08-03	2011-02-10	Galapagos Nv	Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
WO2011015573A1 (en)	2009-08-03	2011-02-10	Galapagos Nv	Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
UA107360C2 (en)	2009-08-05	2014-12-25	Biogen Idec Inc	Bicyclic aryl sphingosine 1-phosphate analogs
EP2462153B1 (en)	2009-08-06	2015-07-29	Isis Pharmaceuticals, Inc.	Bicyclic cyclohexose nucleic acid analogs
US8927553B2 (en)	2009-08-10	2015-01-06	Daljit Singh Dhanoa	Deuterium-enriched alkyl sulfonamides and uses thereof
RU2562861C2 (en)	2009-09-11	2015-09-10	Айсис Фармасьютикалс, Инк.	Modulation of huntingtin expression
US8470987B2 (en)	2009-09-16	2013-06-25	Chiralgen, Ltd.	Protective group for synthesis of RNA and derivative
US20120270929A1 (en)	2009-09-25	2012-10-25	Isis Pharmaceuticals, Inc.	Modulation of ttc39 expression to increase hdl
KR20120083452A (en)	2009-10-15	2012-07-25	화이자 인코포레이티드	Pyrrolo[2,3-d]pyrimidine compounds
TWI475051B (en)	2009-11-18	2015-03-01	Kao Corp	Organic polysiloxane
JP5809408B2 (en)	2009-11-25	2015-11-10	花王株式会社	Hair cosmetics
US8735417B2 (en)	2009-12-17	2014-05-27	Merck Sharp & Dohme Corp.	Aminopyrimidines as Syk inhibitors
AU2009357506A1 (en)	2009-12-28	2012-07-05	Achira Labs Pvt. Ltd.	Diagnostic gel composition, method for making a diagnostic gel composition
JP5822845B2 (en)	2010-01-08	2015-11-25	アイシスファーマシューティカルズ，インコーポレーテッド	Regulation of angiopoietin-like 3 expression
US8750507B2 (en)	2010-01-25	2014-06-10	Cisco Technology, Inc.	Dynamic group creation for managed key servers
EP3208347B1 (en)	2010-02-08	2019-08-14	Ionis Pharmaceuticals, Inc.	Selective reduction of allelic variants
JP6006120B2 (en)	2010-02-08	2016-10-12	アイオーニスファーマシューティカルズ，インコーポレーテッドＩｏｎｉｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Selective reduction of allelic variants
AU2011214468B2 (en)	2010-02-10	2015-05-28	Glaxosmithkline Llc	6-amino-2-{ [ (1S)-1-methylbutyl] oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8H-purin-8-one maleate
US8859755B2 (en)	2010-03-05	2014-10-14	Chiralgen, Ltd.	Method for preparing ribonucleoside phosphorothioate
WO2011127175A1 (en)	2010-04-06	2011-10-13	Isis Pharmaceuticals, Inc.	Modulation of cd130 (gp130) expression
CA2795750A1 (en)	2010-04-07	2011-10-13	Isis Pharmaceuticals, Inc.	Modulation of cetp expression
WO2011133871A2 (en)	2010-04-22	2011-10-27	Alnylam Pharmaceuticals, Inc.	5'-end derivatives
JP6005628B2 (en)	2010-04-28	2016-10-12	アイオーニスファーマシューティカルズ，インコーポレーテッドＩｏｎｉｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Modified nucleosides, analogs thereof, and oligomeric compounds prepared therefrom
US9127033B2 (en)	2010-04-28	2015-09-08	Isis Pharmaceuticals, Inc.	5′ modified nucleosides and oligomeric compounds prepared therefrom
WO2011139911A2 (en)	2010-04-29	2011-11-10	Isis Pharmaceuticals, Inc.	Lipid formulated single stranded rna
US8906607B2 (en)	2010-04-30	2014-12-09	Cellectis	Method for modulating double-strand break-induced homologous recombination
GB201008902D0 (en)	2010-05-27	2010-07-14	Imp Innovations Ltd	Membrane enhanced polymer sythesis
CA2809439A1 (en)	2010-08-31	2012-03-08	Merck Sharp & Dohme Corp.	Novel single chemical entities and methods for delivery of oligonucleotides
US10428019B2 (en)	2010-09-24	2019-10-01	Wave Life Sciences Ltd.	Chiral auxiliaries
US9238812B2 (en)	2010-09-30	2016-01-19	Lsip, Llc	Agent for suppressing expression of dominant mutant gene
KR101381048B1 (en)	2010-10-20	2014-04-14	씨제이제일제당 (주)	A microorganism producing O-phosphoserine and the method of producing L-cysteine or derivatives thereof from O-phosphoserine using the same
DK2632472T3 (en)	2010-10-29	2018-03-19	Sirna Therapeutics Inc	RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
ES2633565T3 (en)	2010-11-12	2017-09-22	The General Hospital Corporation	Non-coding RNAs associated with polycomb
JP6093924B2 (en)	2010-11-30	2017-03-15	株式会社ＷａｖｅＬｉｆｅＳｃｉｅｎｃｅｓＪａｐａｎ	2'-O-modified RNA
WO2012092367A1 (en)	2010-12-28	2012-07-05	University Of Rochester	Nucleic acid binding compounds, methods of making, and use thereof
WO2012109395A1 (en)	2011-02-08	2012-08-16	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising bicyclic nucleotides and uses thereof
WO2012109667A1 (en)	2011-02-12	2012-08-16	University Of Iowa Research Foundation	Therapeutic compounds
US9353371B2 (en)	2011-05-02	2016-05-31	Ionis Pharmaceuticals, Inc.	Antisense compounds targeting genes associated with usher syndrome
FR2975600B1 (en)	2011-05-24	2013-07-05	Assist Publ Hopitaux De Paris	AGENTS FOR THE TREATMENT OF TUMORS
RU2014106024A (en)	2011-07-19	2015-08-27	Юниверсити Оф Айдахо	OPTIONS FOR IMPLEMENTING THE PROBE AND METHODS OF DIRECTED ACTION FOR NUCLEIC ACIDS
AU2012284265B2 (en)	2011-07-19	2017-08-17	Wave Life Sciences Ltd.	Methods for the synthesis of functionalized nucleic acids
EP2742136B1 (en)	2011-08-11	2017-09-27	Ionis Pharmaceuticals, Inc.	Gapped oligomeric compounds comprising 5'-modified deoxyribonucleosides in the gap and uses thereof
EP2751269B1 (en)	2011-08-29	2016-03-23	Ionis Pharmaceuticals, Inc.	Methods and compounds useful in conditions related to repeat expansion
US20140080896A1 (en)	2011-08-30	2014-03-20	The Regents Of The University Of California	Identification of small molecules that facilitate therapeutic exon skipping
EP2751284B1 (en)	2011-08-31	2017-01-11	The University Of Manchester	Method for diagnosing a neurodegenerative disease.
US20140255936A1 (en)	2011-09-09	2014-09-11	Mayo Foundation For Medical Education And Research	Detecting frontotemporal dementia and amyotrophic lateral sclerosis
US10066228B2 (en)	2011-11-30	2018-09-04	Sarepta Therapeutics, Inc.	Oligonucleotides for treating expanded repeat diseases
US10557136B2 (en)	2011-12-12	2020-02-11	Oncolmmunin Inc.	In vivo delivery of oligonucleotides
IN2014CN04590A (en)	2011-12-16	2015-09-18	Nat Univ Corp Tokyo Med & Dent
KR102093604B1 (en)	2011-12-20	2020-03-26	사우디 아람코 테크놀로지스 컴퍼니	Methods for polymer synthesis
CN102675386B (en)	2011-12-24	2014-07-02	河南科技大学	Method for separating and purifying gentiamarin
WO2013134558A1 (en)	2012-03-07	2013-09-12	The Texas A & M University System	Cancer treatment targeting non-coding rna overexpression
CA2866381C (en)	2012-03-13	2020-03-24	Gilead Sciences, Inc.	2'- substituted carba-nucleoside analogs for antiviral treatment
KR20130114435A (en)	2012-04-09	2013-10-17	삼성전자주식회사	Biomolecule detection apparatus including a plurality of electrode
CN104271741A (en)	2012-04-23	2015-01-07	普罗森萨科技有限公司	RNA modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders
NZ702744A (en)	2012-05-22	2016-12-23	Idenix Pharmaceuticals Llc	D-amino acid compounds for liver disease
WO2013179412A1 (en)	2012-05-30	2013-12-05	北海道システム・サイエンス株式会社	Oligonucleotide synthesis method using highly dispersible liquid-phase support
SG11201500239VA (en)	2012-07-13	2015-03-30	Wave Life Sciences Japan	Asymmetric auxiliary group
SG11201500232UA (en)	2012-07-13	2015-04-29	Wave Life Sciences Pte Ltd	Chiral control
BR112015000723A2 (en)	2012-07-13	2017-06-27	Shin Nippon Biomedical Laboratories Ltd	chiral nucleic acid adjuvant
WO2014025805A1 (en)	2012-08-06	2014-02-13	Alnylam Pharmaceuticals, Inc.	Carbohydrate conjugated rna agents and process for their preparation
KR102237882B1 (en)	2012-08-15	2021-04-07	아이오니스 파마수티컬즈, 인코포레이티드	Method of preparing oligomeric compounds using modified capping protocols
US20150275208A1 (en)	2012-10-12	2015-10-01	Isis Pharmaceuticals, Inc.	Selective antisense compounds and uses thereof
EP2906697A4 (en)	2012-10-15	2016-06-22	Ionis Pharmaceuticals Inc	Methods for monitoring c9orf72 expression
BR112015008399A8 (en)	2012-10-15	2017-10-03	Ionis Pharmaceuticals Inc	COMPOUND TO MODULATE C90RF72 EXPRESSION, ITS USE, MODIFIED OLIGONUCLEOTIDE, DOUBLE-STRIP COMPOUND AND COMPOSITION
WO2014062686A1 (en)	2012-10-15	2014-04-24	Isis Pharmaceuticals, Inc.	Methods for modulating c9orf72 expression
EP2725029A1 (en)	2012-10-29	2014-04-30	Laboratoire Biodim	New antibacterial compounds and biological applications thereof
CA2889717A1 (en)	2012-10-29	2014-05-08	Cocrystal Pharma, Inc.	Pyrimidine nucleotides and their monophosphate prodrugs for treatment of viral infections and cancer
EP2915815B1 (en)	2012-10-31	2018-01-17	Takeda Pharmaceutical Company Limited	New modified nucleic acid
BR112015011112A2 (en)	2012-11-15	2018-11-06	Roche Innovation Center Copenhagen A/S	oligomeric compound, oligomer, pharmaceutical composition, use of the oligomeric compound, method of synthesis of an oligomeric compound and method of treating a disease.
DK2922955T3 (en)	2012-11-26	2019-05-13	Roche Innovation Ct Copenhagen As	Compositions and Methods for Modulating FGFR3 Expression
US9211300B2 (en)	2012-12-19	2015-12-15	Idenix Pharmaceuticals Llc	4′-fluoro nucleosides for the treatment of HCV
MX2015009056A (en)	2013-01-30	2015-10-05	Hoffmann La Roche	Lna oligonucleotide carbohydrate conjugates.
WO2014118272A1 (en)	2013-01-30	2014-08-07	Santaris Pharma A/S	Antimir-122 oligonucleotide carbohydrate conjugates
CA2899924A1 (en)	2013-02-04	2014-08-07	Isis Pharmaceuticals, Inc.	Selective antisense compounds and uses thereof
EP3366772A1 (en)	2013-02-22	2018-08-29	Sirna Therapeutics, Inc.	Short interfering nucleic acid (sina) molecules containing a 2' internucleoside linkage
US20160108395A1 (en)	2013-03-01	2016-04-21	National University Corporation Tokyo Medical And Dental University	Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent
CA2907750A1 (en)	2013-03-28	2014-10-02	Syngenta Participations Ag	Methods of controlling neonicotinoid resistant pests
CA2907511A1 (en)	2013-03-28	2014-10-02	Syngenta Participations Ag	Methods of controlling neonicotinoid resistant pests
CN105378085B (en)	2013-05-01	2019-02-15	Ionis制药公司	For adjusting the composition and method of HBV and TTR expression
WO2014189142A1 (en)	2013-05-24	2014-11-27	味の素株式会社	Morpholino oligonucleotide manufacturing method
CA2907694A1 (en)	2013-05-24	2014-11-27	Roche Innovation Center Copenhagen A/S	Oligonucleotide modulators of b-cell cll/lymphoma 11a (bcl11a) and uses thereof
US11028387B2 (en)	2013-05-30	2021-06-08	National University Corporation Tokyo Medical And Dental University	Double-stranded agents for delivering therapeutic oligonucleotides
JP6604544B2 (en)	2013-06-16	2019-11-13	国立大学法人東京医科歯科大学	Double-stranded antisense nucleic acid with exon skipping effect
US20160122761A1 (en)	2013-06-21	2016-05-05	Isis Pharmaceuticals, Inc.	Compositions and methods for modulation of target nucleic acids
MY183049A (en)	2013-06-27	2021-02-09	Roche Innovation Ct Copenhagen As	Antisense oligomers and conjugates targeting pcsk9
TWI657819B (en)	2013-07-19	2019-05-01	美商Ionis製藥公司	Compositions for modulating tau expression
CA2919268C (en)	2013-07-25	2023-09-05	Exicure, Inc.	Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US10435430B2 (en)	2013-07-31	2019-10-08	Ionis Pharmaceuticals, Inc.	Methods and compounds useful in conditions related to repeat expansion
JP2016534127A (en)	2013-09-06	2016-11-04	シンジェンタパーティシペーションズアーゲー	Insecticidal compounds
EP3052511A4 (en)	2013-10-02	2017-05-31	Moderna Therapeutics, Inc.	Polynucleotide molecules and uses thereof
WO2015051214A1 (en)	2013-10-03	2015-04-09	Moderna Therapeutics, Inc.	Polynucleotides encoding low density lipoprotein receptor
WO2015051366A2 (en)	2013-10-04	2015-04-09	Novartis Ag	Novel formats for organic compounds for use in rna interference
CA2926408A1 (en)	2013-10-11	2015-04-16	Ionis Pharmaceuticals, Inc.	Compositions for modulating c9orf72 expression
CA2926341A1 (en)	2013-10-14	2015-04-23	Ionis Pharmaceuticals, Inc.	Methods for modulating expression of c9orf72 antisense transcript
EP3058068B1 (en)	2013-10-14	2019-04-24	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of c9orf72 antisense transcript
US10369201B2 (en)	2013-11-11	2019-08-06	Sangamo Therapeutics, Inc.	Methods and compositions for treating Huntington's disease
CN105722980A (en)	2013-11-14	2016-06-29	罗氏创新中心哥本哈根有限公司	APOB antisense conjugate compounds
EP3053585A1 (en)	2013-12-13	2016-08-10	Moderna Therapeutics, Inc.	Alternative nucleic acid molecules and uses thereof
JPWO2015108046A1 (en)	2014-01-15	2017-03-23	株式会社新日本科学	Chiral nucleic acid adjuvant and antiallergic agent having antiallergic action
US10149905B2 (en)	2014-01-15	2018-12-11	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
WO2015108047A1 (en)	2014-01-15	2015-07-23	株式会社新日本科学	Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
SG10201912897UA (en)	2014-01-16	2020-02-27	Wave Life Sciences Ltd	Chiral design
JP6756700B2 (en)	2014-03-18	2020-09-16	ユニバーシティオブマサチューセッツ	RAAV-based compositions and methods for treating amyotrophic lateral sclerosis
EP3647318B1 (en)	2014-04-28	2021-06-30	Ionis Pharmaceuticals, Inc.	Linkage modified oligomeric compounds
JP2017521045A (en)	2014-05-01	2017-08-03	アイオーニスファーマシューティカルズ，インコーポレーテッドＩｏｎｉｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Compositions and methods for modulating angiopoietin-like factor 3 expression
BR112016025849A2 (en)	2014-05-08	2017-10-17	Chdi Foundation Inc	methods and compositions for the treatment of huntington's disease
CN107075514A (en)	2014-05-20	2017-08-18	衣阿华大学研究基金会	The therapeutic compounds of Huntington's disease
US20160017327A1 (en)	2014-07-11	2016-01-21	The Johns Hopkins University	Phosphorodiamidate morpholino oligomers (pmos) and their use in suppression of mutant huntingtin expression and attenuation of neurotoxicity
CA2955250A1 (en)	2014-07-16	2016-01-21	Moderna Therapeutics, Inc.	Chimeric polynucleotides
EP2982758A1 (en)	2014-08-04	2016-02-10	Centre Hospitalier Universitaire Vaudois (CHUV)	Genome editing for the treatment of huntington's disease
WO2016021683A1 (en)	2014-08-07	2016-02-11	武田薬品工業株式会社	Cationic lipid
WO2016024205A1 (en)	2014-08-15	2016-02-18	Pfizer Inc.	Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene
WO2016037191A1 (en)	2014-09-05	2016-03-10	Health Research, Inc.	Use of huntingtin-derived plasmids and peptides for active immunization as a huntington's disease (hd) therapeutic
US20180112217A1 (en)	2014-11-19	2018-04-26	Roche Innovation Center Copenhagen A/S	Stereospecific Phosphorothioate LNA
JP6689279B2 (en)	2014-12-16	2020-05-20	ロシュイノベーションセンターコペンハーゲンエーエス	Chiral toxicity screening method
KR102636633B1 (en)	2014-12-24	2024-02-13	유니큐어 아이피 비.브이.	RNAi induced Huntingtin gene suppression
US9688707B2 (en)	2014-12-30	2017-06-27	Ionis Pharmaceuticals, Inc.	Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
WO2016112132A1 (en)	2015-01-06	2016-07-14	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of c9orf72 antisense transcript
WO2016127002A1 (en)	2015-02-04	2016-08-11	Bristol-Myers Squibb Company	Lna oligonucleotides with alternating flanks
EP3653712B1 (en)	2015-02-04	2022-11-30	F. Hoffmann-La Roche AG	Tau antisense oligomers and uses thereof
JP6772156B2 (en)	2015-02-04	2020-10-21	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	How to choose a therapeutic molecule
AU2016219396B2 (en)	2015-02-10	2022-03-17	Genzyme Corporation	Variant RNAi
JP2018510621A (en)	2015-02-13	2018-04-19	アルナイラムファーマシューティカルズ，インコーポレイテッドＡｌｎｙｌａｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Patatin-like phospholipase domain-containing 3 (PNPLA3) iRNA compositions and methods of use thereof
US10370659B2 (en)	2015-02-23	2019-08-06	Ionis Pharmaceuticals, Inc.	Compounds and methods for increasing antisense activity
EP3265098A4 (en)	2015-03-03	2019-02-13	Ionis Pharmaceuticals, Inc.	Compositions for modulating mecp2 expression
WO2016145142A1 (en)	2015-03-10	2016-09-15	Emory University	Nucleotide and nucleoside therapeutics compositions and uses related thereto
WO2016154096A1 (en)	2015-03-20	2016-09-29	Ionis Pharmaceuticals, Inc.	Modulation of smggds expression
JP7009356B2 (en)	2015-04-03	2022-01-25	ユニバーシティ・オブ・マサチューセッツ	Oligonucleotide compounds targeting huntingtin mRNA
US10851371B2 (en)	2015-04-10	2020-12-01	Ionis Pharmaceuticals, Inc.	Modulation of SMN expression
WO2016167780A1 (en)	2015-04-16	2016-10-20	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of c9orf72 antisense transcript
US9605263B2 (en)	2015-04-16	2017-03-28	Ionis Pharmaceuticals, Inc.	Compositions for modulating C9ORF72 expression
WO2016209862A1 (en)	2015-06-23	2016-12-29	Alnylam Pharmaceuticals, Inc.	Glucokinase (gck) irna compositions and methods of use thereof
US11414657B2 (en)	2015-06-29	2022-08-16	Ionis Pharmaceuticals, Inc.	Modified CRISPR RNA and modified single CRISPR RNA and uses thereof
US10494632B2 (en)	2015-07-10	2019-12-03	Alnylam Pharmaceuticals, Inc.	Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
EP3320094B1 (en)	2015-07-10	2022-04-13	Ionis Pharmaceuticals, Inc.	Modulators of diacyglycerol acyltransferase 2 (dgat2)
WO2017015109A1 (en)	2015-07-17	2017-01-26	Alnylam Pharmaceuticals, Inc.	Multi-targeted single entity conjugates
MA43072A (en)	2015-07-22	2018-05-30	Wave Life Sciences Ltd	COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
TW201718620A (en)	2015-07-27	2017-06-01	阿尼拉製藥公司	Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof
JP6896703B2 (en)	2015-07-31	2021-06-30	アルナイラムファーマシューティカルズ，インコーポレイテッドＡｌｎｙｌａｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Transthyretin (TTR) iRNA composition for treating or preventing TTR-related diseases and how to use it
JP6835826B2 (en)	2015-08-24	2021-02-24	ロシュイノベーションセンターコペンハーゲンエーエス	LNA-G process
EA201890571A1 (en)	2015-08-25	2018-10-31	Элнилэм Фармасьютикалз, Инк.	METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIOLATION ASSOCIATED WITH THE PROTROTYNCONVERTASE GENE SUBTILYSINE / CEXINOUS TYPE (PCSK9)
EP4393495A3 (en)	2015-09-02	2024-09-25	Alnylam Pharmaceuticals, Inc.	Programmed cell death 1 ligand 1 (pd-l1) irna compositions and methods of use thereof
WO2017059411A1 (en)	2015-10-01	2017-04-06	Memorial Sloan-Kettering Cancer Center	Inhibitors of menaquinone biosynthesis
US10874686B2 (en)	2015-10-01	2020-12-29	Memorial Sloan-Kettering Cancer Center	Anthranilyl-adenosinemonosulfamate analogs and uses thereof
US10577388B2 (en)	2015-10-02	2020-03-03	Roche Innovation Center Copenhagen A/S	Oligonucleotide conjugation process
WO2017062862A2 (en)	2015-10-09	2017-04-13	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods thereof
EP3183347A4 (en)	2015-10-17	2018-04-18	Lifesplice Pharma LLC	Splice modulating oligonucleotides and methods of use thereof
WO2017067970A1 (en)	2015-10-22	2017-04-27	Roche Innovation Center Copenhagen A/S	In vitro toxicity screening assay
WO2017068087A1 (en)	2015-10-22	2017-04-27	Roche Innovation Center Copenhagen A/S	Oligonucleotide detection method
WO2017079291A1 (en)	2015-11-02	2017-05-11	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating c90rf72
CN108291226B (en)	2015-11-12	2022-11-04	豪夫迈·罗氏有限公司	Oligonucleotides for inducing paternal UBE3A expression
CN108779132B (en)	2016-03-13	2022-04-15	波涛生命科学有限公司	Compositions and methods for phosphoramidite and oligonucleotide synthesis
AU2017235278C1 (en)	2016-03-14	2022-03-10	F. Hoffmann-La Roche Ag	Oligonucleotides for reduction of PD-L1 expression
US11267843B2 (en)	2016-03-18	2022-03-08	Roche Innovation Center Copenhagen A/S	Stereodefining L-monomers
US11963972B2 (en)	2016-03-23	2024-04-23	Emory University	Antiviral agents and nucleoside analogs for treatment of Zika virus
AU2017248637A1 (en)	2016-04-13	2018-09-27	Ionis Pharmaceuticals, Inc.	Methods for reducing C9ORF72 expression
US11248019B2 (en)	2016-04-14	2022-02-15	Hoffmann-La Roche Inc.	Trityl-mono-GalNAc compounds and their use
MA45270A (en)	2016-05-04	2017-11-09	Wave Life Sciences Ltd	COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
MA45290A (en)	2016-05-04	2019-03-13	Wave Life Sciences Ltd	PROCESSES AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS
US11261209B2 (en)	2016-05-12	2022-03-01	Roche Innovation Center Copenhagen A/S	Enhanced coupling of stereodefined oxazaphospholidine phosphoramidite monomers to nucleoside or oligonucleotide
JP7083756B2 (en)	2016-05-13	2022-06-13	エフ．ホフマン－ラロシュアーゲー	Protein-based sample recovery matrix and equipment
US10882884B2 (en)	2016-05-18	2021-01-05	Eth Zurich	Stereoselective synthesis of phosphorothioate oligoribonucleotides
US11013757B2 (en)	2016-06-03	2021-05-25	Wave Life Sciences Ltd.	Oligonucleotides, compositions and methods thereof
CN109310765A (en)	2016-06-20	2019-02-05	领先基因生物技术股份有限公司	Antibody-drug conjugates
WO2018022473A1 (en)	2016-07-25	2018-02-01	Wave Life Sciences Ltd.	Phasing
WO2018098264A1 (en)	2016-11-23	2018-05-31	Wave Life Sciences Ltd.	Compositions and methods for phosphoramidite and oligonucleotide synthesis
EP3630788A4 (en)	2017-06-02	2021-04-28	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods of use thereof
EP3630789A4 (en)	2017-06-02	2021-06-16	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods of use thereof
US11603532B2 (en)	2017-06-02	2023-03-14	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods of use thereof
WO2018237194A1 (en)	2017-06-21	2018-12-27	Wave Life Sciences Ltd.	Compounds, compositions and methods for synthesis
AU2018316159A1 (en)	2017-08-08	2020-02-06	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods thereof
JP7472018B2 (en)	2017-09-18	2024-04-22	ウェーブライフサイエンシーズリミテッド	Techniques for preparing oligonucleotides
JP2020537518A (en)	2017-10-12	2020-12-24	ウェーブライフサイエンシーズリミテッド	Oligonucleotide composition and its method
KR20210005057A (en)	2018-04-12	2021-01-13	웨이브 라이프 사이언시스 리미티드	Oligonucleotide composition and method of use thereof
EP3790596A4 (en)	2018-05-11	2022-04-06	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods of use thereof
US20220186217A1 (en)	2018-12-06	2022-06-16	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods thereof
SG11202107318YA (en)	2019-02-01	2021-08-30	Wave Life Sciences Ltd	Oligonucleotide compositions and methods thereof
KR20210149750A (en)	2019-03-20	2021-12-09	웨이브 라이프 사이언시스 리미티드	Techniques useful for preparing oligonucleotides
JPWO2020196662A1 (en)	2019-03-25	2020-10-01
WO2020219981A2 (en)	2019-04-25	2020-10-29	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods of use thereof
SG11202111387YA (en)	2019-04-25	2021-11-29	Wave Life Sciences Ltd	Oligonucleotide compositions and methods of use thereof
WO2020227691A2 (en)	2019-05-09	2020-11-12	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods of use thereof
AU2020363391A1 (en)	2019-10-06	2022-03-24	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods of use thereof
IL291974A (en)	2019-10-06	2022-06-01	Wave Life Sciences Ltd	Oligonucleotide compositions and methods of use thereof

2013
- 2013-07-12 SG SG11201500239VA patent/SG11201500239VA/en unknown
- 2013-07-12 DK DK13817386.9T patent/DK2872485T3/en active
- 2013-07-12 JP JP2015500697A patent/JP6268157B2/en active Active
- 2013-07-12 BR BR112015000784A patent/BR112015000784A8/en not_active Application Discontinuation
- 2013-07-12 CN CN201380037512.9A patent/CN104684893B/en active Active
- 2013-07-12 EP EP20214250.1A patent/EP3812370A1/en active Pending
- 2013-07-12 CA CA2879023A patent/CA2879023C/en active Active
- 2013-07-12 ES ES13817386T patent/ES2862073T3/en active Active
- 2013-07-12 US US14/414,604 patent/US9598458B2/en active Active
- 2013-07-12 CN CN201610835862.5A patent/CN107011400B/en active Active
- 2013-07-12 EP EP13817386.9A patent/EP2872485B1/en active Active
- 2013-07-12 WO PCT/JP2013/004303 patent/WO2014010250A1/en active Application Filing
- 2013-07-12 PT PT138173869T patent/PT2872485T/en unknown
- 2013-07-12 RU RU2015100197A patent/RU2693381C2/en not_active Application Discontinuation
- 2013-07-12 PL PL13817386T patent/PL2872485T3/en unknown
- 2013-07-12 KR KR1020157004038A patent/KR101850319B1/en active IP Right Grant
- 2013-07-12 AU AU2013288048A patent/AU2013288048A1/en not_active Abandoned
2016
- 2016-07-08 AU AU2016204770A patent/AU2016204770B2/en active Active
- 2016-10-14 US US15/294,602 patent/US10167309B2/en active Active
2017
- 2017-10-30 JP JP2017209854A patent/JP6608413B2/en active Active
2018
- 2018-04-26 AU AU2018202884A patent/AU2018202884B2/en active Active
- 2018-11-06 US US16/182,302 patent/US10696711B2/en active Active
2019
- 2019-08-21 JP JP2019150815A patent/JP7030749B2/en active Active
2020
- 2020-05-19 US US16/878,461 patent/US11136346B2/en active Active
- 2020-08-10 AU AU2020213420A patent/AU2020213420B2/en active Active
2021
- 2021-09-02 US US17/465,238 patent/US20220127301A1/en active Pending
2022
- 2022-02-22 JP JP2022026049A patent/JP7390417B2/en active Active
2023
- 2023-03-20 AU AU2023201700A patent/AU2023201700A1/en active Pending
- 2023-11-17 JP JP2023196280A patent/JP2024023334A/en active Pending

Also Published As

Publication number	Publication date
JP6268157B2 (en)	2018-01-24
KR20150039777A (en)	2015-04-13
WO2014010250A1 (en)	2014-01-16
AU2023201700A1 (en)	2023-04-13
PL2872485T3 (en)	2021-05-31
JP2024023334A (en)	2024-02-21
US9598458B2 (en)	2017-03-21
CA2879023A1 (en)	2014-01-16
US11136346B2 (en)	2021-10-05
JP2015523316A (en)	2015-08-13
US10696711B2 (en)	2020-06-30
AU2018202884A1 (en)	2018-05-17
AU2016204770B2 (en)	2018-05-10
BR112015000784A8 (en)	2018-04-03
JP7390417B2 (en)	2023-12-01
EP2872485A4 (en)	2015-12-30
EP3812370A1 (en)	2021-04-28
US20170029445A1 (en)	2017-02-02
EP2872485A1 (en)	2015-05-20
US10167309B2 (en)	2019-01-01
AU2018202884B2 (en)	2020-05-14
AU2020213420B2 (en)	2022-12-22
JP2020015735A (en)	2020-01-30
AU2016204770A1 (en)	2016-07-28
CN104684893A (en)	2015-06-03
EP2872485B1 (en)	2020-12-16
AU2013288048A1 (en)	2015-01-22
BR112015000784A2 (en)	2017-06-27
JP6608413B2 (en)	2019-11-20
JP2018058845A (en)	2018-04-12
JP2022071016A (en)	2022-05-13
DK2872485T3 (en)	2021-03-08
CN104684893B (en)	2016-10-26
PT2872485T (en)	2021-03-05
KR101850319B1 (en)	2018-04-20
CN107011400A (en)	2017-08-04
US20200385420A1 (en)	2020-12-10
US20190177357A1 (en)	2019-06-13
ES2862073T3 (en)	2021-10-06
AU2020213420A1 (en)	2020-08-27
RU2015100197A (en)	2016-09-10
US20150197540A1 (en)	2015-07-16
CA2879023C (en)	2017-03-28
RU2693381C2 (en)	2019-07-02
CN107011400B (en)	2021-05-25
US20220127301A1 (en)	2022-04-28
JP7030749B2 (en)	2022-03-07

Publication	Publication Date	Title
SG11201500239VA (en)	2015-03-30	Asymmetric auxiliary group
DK3327112T3 (en)	2020-05-04	Agse-deficient stamme
EP2754580A4 (en)	2015-06-24	Dumptruck
EP2935220A4 (en)	2016-04-27	Peri-carbinols
GB201411223D0 (en)	2014-08-06	None
EP2920142A4 (en)	2016-08-10	Methanofullerenes
EP2812698A4 (en)	2015-09-23	Dual-acceptor time-resolved-fret
EP2920157A4 (en)	2016-05-11	Di-macrocycles
EP2873363A4 (en)	2016-03-02	Diopsimeter
GB2500883B (en)	2015-05-27	Improved saw-horse
EP2834250A4 (en)	2015-10-14	Lithiumsilicate
GB201203307D0 (en)	2012-04-11	Remvox
GB201410091D0 (en)	2014-07-23	None
ZA201305187B (en)	2014-04-30	Improved brattice
GB201207154D0 (en)	2012-06-06	Novel form
AU345893S (en)	2012-12-04	Treehouse
GB201203962D0 (en)	2012-04-18	Locnlatch
GB201203844D0 (en)	2012-04-18	Salvacubo
GB201203776D0 (en)	2012-04-18	Sili-m8
GB201203808D0 (en)	2012-04-18	MicBooth
GB201203815D0 (en)	2012-04-18	Mini-meals
GB201203612D0 (en)	2012-04-18	Ishopfront
GB201203604D0 (en)	2012-04-18	Envelope-box
GB201203507D0 (en)	2012-04-11	Keynut
GB201203453D0 (en)	2012-04-11	TVtidy